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Rett syndrome (RTT) is an X-linked form of mental retardation that occurs sporadically once 
every 10,000-15,000 female births. After a period of normal development (6-18 months), the 
patients show a rapid regression of acquired speech and motor skills and the development of 
several symptoms including mental retardation, seizures, intermittent hyperventilation and 
stereotypic hand movements. This condition is mainly stable and signs of progressive 
neurodegeneration are absent. Almost 80% of Rett cases are associated with mutations in the 
MECP2 (methyl CpG binding protein 2) gene. MeCP2 is a nuclear protein that binds 
methylated DNA and recruits histone deacetylases and co-repressor complexes to suppress 
transcription. It belongs to the MBD family of proteins involved in the epigenetic regulation 
of gene-expression. 
Recently, mutations in the X-linked gene cyclin-dependent kinase-like 5 (CDKL5) have been 
found in patients characterized by a subset of Rett clinical phenotypes and generally suffering 
of infantile spasms and severe mental retardation. The product of CDKL5 is a serine/threonine 
kinase that belongs to the CMGC family; the exact functions exerted by this kinase and its 
regulatory mechanisms remain mainly unknown. 
CDKL5 is present in the nucleus and in the cytosol of neurons and its expression shows a 
continued increase during development; accordingly, CDKL5 is a critical regulator of 
neuronal morphogenesis, neurite growth and dendritic arborization. In the cytosol, CDKL5 
phosphorylates NGL-1 (Netrin-G1 Ligand 1), a regulator of early synapse formation and 
maturation. In the nucleus, CDKL5 binds and phosphorylates in vitro MeCP2.  Furthermore, 
in the nucleus CDKL5 colocalizes with nuclear speckles and is probably involved in the 
regulation of mRNA splicing. 
Recently our group has demonstrated that the expression levels and the subcellular 
distribution of CDKL5 are modified by neuronal activation. In particular, a glutamate bath 
induces in cultured hippocampal neurons the rapid exit of the kinase from the nucleus and its 
proteasome-dependent degradation. The significance of this response remains to be 
elucidated. Furthermore, BDNF induces in rat cortical cultures, a rapid phosphorylation of 
CDKL5.   
The main aim of this work was to study how neuronal depolarization or activation by BDNF 
affects Cdkl5 regulation, in terms of gene transcription, post translation modifications of its 
final protein product and the involved signaling pathway(s). We found that, both in primary 
murine neuronal cultures and cortical slices, depolarization affects the expression of the gene, 
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both at the transcriptional and post-transcriptional levels, together with its phosphorylation 
state. The response is affected by the maturation stage of the treated neurons and the involved 
signaling pathways have been characterized. We speculate that the observed regulation of 
Cdkl5 during neuronal depolarization could be related to a role of the kinase in neuronal 
activation.  Electrophysiological approaches will be required to confirm the involvement of 
CDKL5 in the regulation of neuronal activity; furthermore, the identification of novel 
interactors of Cdkl5 should help in understanding its physiological functions in the central 






























Rett syndrome (RTT) is a severe progressive neurodevelopmental disorder mainly affecting 
female patients during early childhood. The prevalence is estimated to be approximately one 
in 10.000/15.000 females [1]. Pediatric patients with RTT develop normally up to 6–18 
months of age when the development unexpectedly slows down and the patients show general 
growth retardation, weight loss and muscle hypotonia. Deceleration of head growth, a sign 
linked to the neurological involvement, is very precocious and leads to microcephaly within 
the second year of life. Simultaneously,  stagnation and progressive loss of the cognitive skills 
that patients had previously gained (speech, purposeful hand use) occur. Patients start 
presenting autistic features (self-abusive behavior, irritability, loss of visual contact, loss of 
speech and social skills, indifference to the environment) and characteristic repetitive hand 
stereotypies (typically wringing/washing hand-movements, but also flapping and mouthing). 
Other signs, proving an involvement of the central nervous system (CNS), are the loss of 
motor coordination, the deterioration of autonomic functions,  breathing irregularities 
(hyperventilation followed by breath-holding and apnea) and sleep disorders [2,3]. Seizures 
are common in Rett syndrome (50-80% of cases [4]), often starting at 2-3 years of age and 
becoming most common with age through puberty.  The occurrence of seizures is described 
as a factor associated with the worst clinical phenotype. No correlation between seizure-onset 
and head growth has been established [4]. Seizures range from easily controlled to medically 
refractory epilepsy, but the most common presentation is given by partial complex and tonic-
clonic seizures [5]. Between 5 to 10 years of age it is possible to see an improvement in the 
autistic features and in the communication skills of the patients, although they continue to 
have major physical problems as osteopenia, scoliosis, and rigidity. Also emotional disorders 
like night crying, irritability, low mood and anxiety become less evident  [6,7,8]. Adolescent 
girls are characterized by a severe worsening of the motor abilities consisting of rigidity, 
curvature of the spine and spasticity associated with deformity. Some autonomic problems 
can also become more acute (cold blue feet, constipation, tachy-bradycardia).  During 
adolescence, cognition and social skills in general do not decline and a decrease of hand 
stereotypies may be observed [3,9]. Summarizing, the clinical outcome can be subdivided in 4 








Tab.1 Typical RTT syndrome clinical outcome 
 
 
Period Clinical features 
STAGE 1  
 
“Developmental stagnation” 
6-18 months of age 
 
decreasing head growth  
reduced eye contact  
reduced interest in environment 
delayed motor development 
 
STAGE 2  
 
“Developmental regression”  
1-3 years of age 
 
loss of acquired hand and speech skills 
stereotypies and motor difficulties 
regression of social communication  
autistic-like symptoms  




“Stationary state - Seizures” 
3-10 years of age 
 
onset of seizures 
motor difficulties 










spasticity and deformity   






Historical overview of RTT and diagnostic criteria 
 
Andreas Rett in 1966 published the first description of a girl with the syndrome that later got 
his name [10]; worldwide recognition of RTT was obtained in 1983 when Hagberg and 
colleagues published a report describing 35 cases [11].  
In 1985, Dr. Hagberg developed consensus criteria exclusively for females [12], which were 
afterwards modified (1988) to include also males [13]. Subsequently, after the identification 
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of the gene involved in most cases of typical RTT [14], those criteria were further modified to 
achieve a major diagnostic selectivity (International Consensus Meeting, European Paediatric 
Neurology Society, Baden 2001). Consequently Hagberg proposed necessary and supportive 
diagnostic criteria [15,16] for typical RTT syndrome, which were further revised in 2010 by 
the RettSearch Consortium, an international group of clinicians (Tab.2) [17]. The criteria 
proposed by Hagberg and revised in 2010 underline the concept of “regression” (“loss” of 
purposeful hand skills,  “loss” of acquired speech, “regression followed by recovery or 
stabilization”). The importance of regression for the diagnosis of RTT was described since 
1986, when Goutieres and Aicardi wrote: “The absence of normal initial development, 
followed by secondary deterioration and of loss of previously acquired voluntary hand grasp 
is especially important, as it is one of the essential traits of Rett Syndrome” [18]. 
In 1985, Dr. Hanefeld described a girl with infantile spasms who also developed many 
characteristics of RTT syndrome. Soon after the “Hanefeld variant” of RTT (infantile spasms, 
early-onset seizures and RTT-like features) was reported, the discovery of a large number of 
other clinical variations led the International Medical Community to draw up an increasing 
list of “atypical” manifestations of RTT, leading to the identification of clinically independent 
entities. Consequently, the development  of consensus criteria for variant forms of RTT 
became important [19]. More recently, RettSearch Consortium completed the review of the 
main criteria for the diagnosis of atypical RTT [17] (Tab. 2), including those core features 
that are essential to clarify the diagnosis of RTT or its variants [20]. The presence of 
regression in atypical RTT syndrome was emphasized, although the timing of appearance is 
different in comparison with typical RTT. In typical RTT syndrome the regression is 
generally present at the age of 6 months, while in atypical RTT syndrome it could be delayed. 
Although the majority of patients carrying mutations in CDKL5 (cyclin-dependent kinase-like 
5) are female, there are rare occurrences in males suffering from infantile spasms, early-onset 
epilepsy and severe mental retardation [3].  
To summarize, several clinically defined variant forms of RTT have been recognized, but 
three distinct forms are the most frequent: a) the preserved speech variant, or “Zappella-RTT” 
(hand stereotypies, regression, autism), b) the congenital variant  (hypotonia and mental 
retardation from the very first months of life), c) the early-onset seizure variant (Hanefeld 







Tab.2 RTT Diagnostic Criteria (adapted from Neul et al., 2010 [17]) 
 
RTT Diagnostic Criteria 2010  
Main Criteria 
 
1.  Partial or complete loss of acquired purposeful hand skills 
2.  Partial or complete loss of acquired spoken language 
3.  Gait abnormalities: impaired (dyspraxic) or absence of ability. 
4.  Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping,  
mouthing and washing/rubbing automatisms 
 
Required for typical or classic RTT 
 
1.  A period of regression followed by recovery or stabilization 
2.  All main criteria and all exclusion criteria 
3.  Supportive criteria are not required, although often present in typical RTT 
 
Required for atypical or variant RTT 
 
1.  A period of regression followed by recovery or stabilization 
2.  At least 2 out of the 4 main criteria 
3.  5 out of 11 supportive criteria 
 
Exclusion Criteria for typical RTT 
 
1.  Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe 
infection that causes neurological problems 
2.  Grossly abnormal psychomotor development in first 6 months of life 
 
Supportive Criteria for atypical RTT 
 
1.  Breathing disturbances when awake 
2.  Bruxism when awake 
3.  Impaired sleep pattern 
4.  Abnormal muscle tone 
5.  Peripheral vasomotor disturbances 
6.  Scoliosis/kyphosis 
7.  Growth retardation 
8.  Small cold hands and feet 
9.  Inappropriate laughing/screaming spells 
10.  Diminished response to pain 







Typical RTT syndrome is related to MECP2-gene mutations 
 
Given that the majority of patients with RTT are females, it had been speculated for many 
years that genetic defects in the X chromosome might be involved and that an X-linked 
dominant mode of inheritance could explain the male lethality in this condition. RTT 
syndrome was initially described as a “postnatal phenotypic manifestation of a prenatal 
developmental alteration” [21,22] and linkage studies were not possible, since more than 99% 
of RTT cases are sporadic.  However, in 1998 a family with a maternal inheritance was 
identified, permitting exclusion mapping studies and leading to the identification of the Xq28 
locus (1-5) as a candidate region for the involved gene. Using a systematic gene screening 
approach, Amir and colleagues identified the first mutations in the MECP2-gene (methyl CpG 
binding protein 2) in 5 sporadic cases. It is now clear that not all RTT patients carry mutations 
in MECP2; indeed, by considering typical RTT patients, MECP2 mutations can be identified 
in almost 90-95% of cases. The number of MECP2-negative patients increase to up to 30-




MeCP2 structure and functions 
 
The MECP2 gene is located at q28 of the human X chromosome and four exons code for the 
two different isoforms of the protein derived from alternative splicing of exons 1 and 2.  
Furthermore, four different transcripts, differentially expressed in nervous and non-nervous 
tissues, can be alternatively generated because of a large 3’-untranslated region containing 
multiple polyadenylation sites.  
The MECP2 gene codes for a nuclear protein, MeCP2, that constitutes the founding member 
of the Methyl-CpG binding protein family. Indeed, MeCP2 was isolated in 1992 as a protein 
capable of binding selectively to methylated DNA containing just one single symmetrically 
methylated CpG [23]. MeCP2 is composed of four functional domains (Fig.1): the methyl-
binding domain (MBD), the transcriptional repression domain (TRD), a nuclear localization 
signal (NLS) and the WW domain binding region [123]. The MBD, located in the N-
terminus, is sufficient to direct specific binding to methylated DNA whereas the TRD, located 
in the central core of the protein, recruits transcriptional corepressors such as c-Ski, N-CoR 
and mSin3A, which interact with class I histone deacetylases, therefore regulating chromatin 
conformation and gene-transcription. The WW domain (also known as WWP domain) of the 
MeCP2 interactors is a short domain with two signature tryptophan residues, that provides a 
platform for the assembly of multiprotein networks involved in molecular processes, such as 
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Figure 1. A schematic representation of MeCP2 illustrating the positions of the methyl-CpG-binding domain 
(MBD), the nuclear localization signal (NLS) and the transcriptional repression domain (TRD). Phosphorylation 




The expression of MeCP2 is ubiquitous in peripheral tissues and in CNS, with highest 
expression levels in neurons. During embryogenesis, the expression levels of MeCP2 in 
neurons increase [25] and correlate with the maturation of the central nervous system; indeed, 
in mouse, Mecp2 appears first in ontological older tissues (spinal cord and brainstem) and 
then in cortex, where the expression in deeper cortical layers precedes that in the superficial 
layers [26]. The modulation of MeCP2 expression is complete only when cells reach maturity 
and, in humans (but not in mice), expression increases also during the post-natal period (until 
the age of 10 years).  
The functions of MeCP2 in the nucleus are mainly directed to the regulation of gene 
expression in the context of epigenetic mechanisms linked to the presence of methylated 
DNA sequences. 
Considering the well-known role of DNA methylation in transcriptional silencing, several 
laboratories have used candidate approaches and genome-wide expression profile studies to 
identify direct target genes of MeCP2. These studies have contributed to the notion that 
MeCP2 might function as transcriptional repressor of brain derived neurotrophic factor 
(BDNF) gene [27-29]. However, this first suggestion has not always been confirmed by 
following reports and so far no bona fide MeCP2-target genes are univocally recognized. Also 
the first classification of MeCP2 as a transcriptional repressor is reductive considering a 
recent work showing the ability of MeCP2 to activate the transcription of some genes through 
the association with CREB1 [30,31].  Furthermore, it has been demonstrated that MeCP2 can 
function as an architectural chromatin protein, functioning directly without corepressor or 
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enzymatic activities [39]. Indeed, depending on the molar ratio of MeCP2 to nucleosomes, 
MeCP2 assembles novel secondary and tertiary chromatin structures. Importantly, recent data 
finely measuring the abundance of MeCP2 in neurons have led to hypothesize that in brain 
MeCP2 could be considered a global regulator of chromatin architecture, coating all 
chromosomes by tracking methylated DNA. In accordance with a structural role of MeCP2, 
its deficiency leads to global changes in chromatin structure, such as an increase in histone 
acetylation and H1 levels. Indeed, MeCP2 can substitute histone H1 in methylated chromatin 
[32,33].  
Besides a role of MeCP2 in regulating gene expression and chromatin structure, a role in 
regulating protein synthesis has also been hypothesized. Indeed, a recent publication has also 
shown that both Mecp2-null hemizygous males and heterozygous females are characterized 
by a reduction in the AKT/mTOR signaling (a crucial pathway involved in controlling 
neuronal cell soma, dendrite arborization, synaptic function, structure and plasticity) and a 
significant impairment in protein synthesis [39]. It is worthwhile to recall that aberrant 
neuronal protein synthesis is considered a probable cause of the clinical features of autism 
spectrum disorders; thus these data might suggest a novel, direct or indirect function of 
MeCP2 that could be relevant for understanding the pathogenesis of RTT. 
A second mechanism by which MeCP2 could be implicated in the regulation of protein 
synthesis is represented by its role in mRNA-splicing processes. Indeed, in the mammalian 
brain,  MeCP2 directly interacts with the splicing factor Prpf3 (pre-mRNA processing factor 
3), forming a novel brain-derived MeCP2 complex proposed to regulate mRNA splicing. This 
function of MeCP2 could be related with RTT pathophysiology, since many MECP2 RTT 
truncations disrupt the MeCP2-Prpf3 complex, probably leading to the aberrant mRNA 
splicing evident in a mouse model for RTT [40]. 
A new approach for the comprehension of MeCP2 functions is given by the study of its site-
specific phosphorylation. Indeed, it has been demonstrated that MeCP2 functions in the 
nucleus are regulated by specific events of phosphorylation that affect its activity in response 
to extracellular cues. In particular, in rodent brain, serine 80 (S80) and S399 are the two major 
phosphorylation sites of MeCP2 under resting conditions, whereas S424 and S421 show 
specific depolarization-dependent phosphorylation [37, 38]. It has been suggested that S80 
phosphorylation increases the affinity of MeCP2 for euchromatin whereas the modification of 
S421 was found in vitro to lead to a decrease in the binding of MeCP2 to specific methylated 
promoters. We still need to reveal the consequences of these post-translational modifications 
for gene expression. Furthermore, very recent ChIP-seq analyses of the phosho-S421 isoform 
of MeCP2 suggest that in vivo this form is globally bound to methylated DNA, therefore 
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questioning once again the previous results. Furthermore, the kinases and the phosphatases 
involved in the post-translational modifications of MeCP2 remain mainly uncharacterized 
even though the involvement of CaMKIV in the phosphorylation of S421-MeCP2 and of 
HIPK2 in S80 phopshorylation have been suggested. CDKL5, the kinase mutated in some 
patients with a RTT variant (see below), is also capable of phosphorylating MeCP2 in vitro 
on yet non-identified sites [41]. This observation underlines the importance of MeCP2-
phosphorylation in the clinical presentation of RTT [243].  Accordingly, some symptoms 
observed in RTT patients, such as the weight gain and the decreased locomotor activity, are 
also present in a knock-in mouse model carrying a substitution of S80 with the non-







So far, hundreds of different mutations in MECP2 have been described, including missense, 
nonsense, frameshift mutations, wide deletions of whole exons and complex rearrangements. 
Eight missense and nonsense mutations (in the MBD and in the TRD) account for 
approximately 70% of all mutations. These so called “hot spot mutations” are C to T 
transition mutations, probably caused by unrepaired deamination of methylated cytosine bases 
in the paternal germline.  Small C-terminal deletions account for approximately 10% of 
mutations: indeed, a section with repetitive sequence elements between nucleotides 1050 and 
1200, encoding the C-terminus of MeCP2, is a hot spot for this kind of deletions and for 
larger rearrangements present in around the 16% of the remaining patients. Alterations in the 
expression levels of MeCP2 could also be related to neurologic disfunctions, like the MECP2 
duplication syndrome (hypotonia, mental retardation, poor speech development, progressive 
spasticity, seizures), 100% penetrant in males [124,125]. Mouse models have confirmed that 
RTT-like features can be caused both by loss of expression, underexpression and 
overexpression of Mecp2 [42,43]; this is important considering that the MeCP2 levels are 
sensitive also to the presence of some point mutations [44].    
The establishment of a link between genotype and phenotype in RTT patients is not easy 
because of the X-chromosome inactivation that renders females mosaics for the mutation  
[45].  However, several genotype-phenotype correlation studies have been reported and some 
data are starting to emerge. Some clinical differences between patients with truncating versus 
missense mutations have been described [46]. Generally, point mutations involving the MBD 
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or the NLS, affecting the possibility of MeCP2 to bind methylated DNA, and truncating 
mutations in the N-terminus of the protein lead to a more severe phonotype [79]. On the 
contrary, point mutations affecting the TRD (e.g. R306C, associated only with language 
disabilities [77]) or late-truncating mutations, where the functions of the protein are partially 
conserved,  are usually associated with a less severe phenotype [78]. In a large cohort of 
typical RTT syndrome, patients with the early truncating mutation R168X  showed very poor 
abilities to walk, to use the hands and to speak in comparison with the patients carrying the 
R294X truncation [77].  In addition, different mutations in the MBD, probably affecting DNA 
binding to different degrees, are related to more severe (e.g. T158M, a mutation found in 




Atypical RTT syndrome is frequently caused by mutation in genes other 
than MECP2 
 
Mutations in loci other than MECP2 have been found in some atypical RTT patients. In 
particular, the genes identified so far are related to two different and well characterized RTT 
variants:  the early-onset seizure variant and the congenital form. The first gene to be 
identified was CDKL5, located on the X-chromosome and coding for the serine-threonine 
kinase cyclin-dependent kinase-like 5. Mutations in CDKL5 were for the first time described 
in 2003 [47] in two unrelated epileptic patients, at the age of respectively two and three 
months, with identical phenotypes: early-onset severe infantile spasms, global developmental 
arrest, hypsarrhythmia and severe mental retardation. In 2004, Weaving et al. demonstrated 
for the first time the presence of CDKL5-mutations in a girl with a RTT-overlapping 
phenotype, in her sister with autistic disorder and in her brother with profound intellectual 
disability and seizures who died at the age 16 years. MECP2 mutations were absent in these  
patients and three candidate regions were identified by microsatellite mapping (Xp22.31-pter; 
Xp22.12-p22.11 and Xq21.33); the authors sequenced two genes, the ARX and CDKL5 genes, 
located within the Xp22 region, leading to the establishment  of the involvement of CDKL5 in 
RTT [48]. In 2005, Scala et al. [80], by analyzing two MECP2-negative patients affected by 
the Hanefeld variant of RTT and by considering the clinical overlap between the Hanefeld 
variant and West syndrome,  studied the same two genes CDKL5 and ARX; CDKL5 
frameshift deletions were found in both patients, confirming the involvement of this gene in 
RTT. It is important to mention that CDKL5 mutations have never been found in patients with 
typical Rett syndrome, thus linking this gene to a very specific clinical picture.  
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The second gene involved in atypical RTT syndrome was identified by Ariani et al. [49] in 
2008; the authors reported the presence of FOXG1-gene truncation mutations in two patients 
affected by the congenital variant of Rett syndrome. The FOXG1 gene is located on 






CDKL5 structure  
 
The human CDKL5 gene (Xp22 [50,51]) is composed of 24 exons of which the first three 
(exons 1, 1a and 1b) are untranslated [52]. Due to alternative splicing of exons 19-21 and 
exon 16b, four different hCDKL5 isoforms might exist, differing within the C-terminal 
region. The first isoform to be identified was the 1030 a.a. protein (CDKL5-115; 115 kDa) 
that is specific for primates and is mainly expressed in testis. A second isoform is a 960 a.a. 
protein (CDKL5-107; 107 kDa), conserved in human and mouse, that seems to be the 
predominant one in brain. The presence of exon 16b would generate the CDKL5-115+ex.16b 
and/or CDKL5-107+ex.16b (Fig.2). At the functional level,  the only difference that has been 
observed between these isoforms  is their stability:  in fact, CDKL5-107 appears to be more 
stable than the longer human CDKL5-115 isoform [53]. Considering the first non-translated 
exons (1, 1a and 1b), other two CDKL5-mRNA splice variants with distinct 5‘UTRs have 
been found: isoform I, containing exon 1, is present in a wide range of tissues, whereas 



























Fig.2 The genomic structure of CDKL5 and its splice variants. 
A) The human CDKL5 gene can be subdivided in 6 regions: I) the non translated exons 1, 1a and 1b (gray), II) 
the exons encoding the catalytic domain (blue), III) the exons encoding the common C-terminal region 
(white), IV) exons 19-21 specific for CDKL5-115 (red), V) exon  16b (green), VI) intron 18 retained in 
CDKL5-107 (hatched).  
B) Human CDKL5 protein isoforms differing in the C-terminal region (the color code corresponds to that of 
panel A).   
C) The murine CDKL5 isoforms. a) mCDKL5-105 harbors a distinct C-terminal region encoded by a mouse-




In expression studies in human and mouse tissues, the CDKL5/Cdkl5 mRNA was detected in 
a wide range of peripheral districts such as testis, lung, spleen, placenta, uterus and prostate, 
but highest levels were found in the brain [50,52,53].  
Cdkl5-mRNA levels in adult mouse brain are particularly high in the forebrain. Interestingly, 
higher expression levels are detected in the most superficial cortical layers, involved in the 
intercortical connectivity. In particular, there are some cortical areas in which the mRNA-
expression is more evident (the frontal cortex,  the motor cortex and the cingulate gyrus), 
suggesting a region specific role of CDKL5 and the putative involvement of the kinase in 




in the entorhinal cortex and in the hippocampus might suggest an involvement of CDKL5 in 
high cognitive functions like learning, memory, and the development of individuality. 
Between different neuronal sub-populations, there are also differences in the expression of 
Cdkl5: the glutamatergic and the gabaergic neurons (the main populations in the striatum) are 
the two cellular types expressing highest CDKL5 levels in brain; in particular, Cdkl5 is 
expressed in both glutamatergic and GABAergic primary mouse cultured neurons, but is 
certainly better detectable in the latter cell type [52,54]. Specific future experiments are 
required to explain the role and the regulatory mechanisms of Cdkl5 expression in different 
brain regions, including the thalamic geniculate nuclei and the cerebellum where the 
transcripts are also detected even if at later stages.  
Studies of CDKL5-protein expression applied to adult rat extracts mainly confirmed the 
mRNA-expression studies [56]. At the cellular level, the kinase is highly expressed in 
virtually all NeuN-positive neurons while very low levels are present in the glia [56].  In 
mouse brain, the kinase is widely distributed in hippocampus, cortex, thalamus, and striatum, 
mainly in neurons [52,54]. 
The expression profile of Cdkl5 is finely regulated during development: indeed, the kinase is 
only minimally detectable at embryonic stages, it is induced during late pre-natal and early 
post-natal stages and its levels increase till reaching a plateau at P14 [54].  
The CDKL5 gene codes for a serine-threonine kinase, named CDKL5 (Cyclin-Dependent 
Kinase–Like 5), belonging to the CMGC family of kinases which includes the family of 
cyclin-dependent kinases (CDK), the mitogen-activated protein kinases (MAP kinases or 
extracellular-signal-regulated kinases (ERKs)), the glycogen synthase kinases  (GSK) and 
the CDK-like kinases. 
The catalytic domain of CDKL5 is homologous to that of the other CDKL-family members, 
while the presence of a long C-terminus of more than 600 amino acids is unique for CDKL5.   
The catalytic domain of CDKL5 (Fig. 3), which is located in the N-terminal portion of the 
protein (13-297 a.a.), presents three kinase signatures homologous to other serine–threonine 
kinases: 
 
1) the ATP-binding motif, located between amino acids 13-43 a.a., with a glycine-rich 
stretch close to a lysine residue (K42) involved in ATP binding [60]; 
 
2) the serine/threonine protein kinase active site, between amino acids 127-144, with a 
conserved aspartic acid (D135) important for the catalytic activity  [60];  
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3) the “activation-loop” with a DFG domain and a TEY motif 
(DFGFARNLSEGNNANYTEY; 153-171 a.a.). It is important to mention that the 
universally conserved DFG motif forms polar contacts with other regions of the kinase, 
stabilizing its active conformation either directly or through the coordination of 
magnesium atoms; the TEY motif, mainly studied in the activation loop of ERK kinases 
is dually phosphorylated during activation by the MEK-MAPKK (MAPK/ERK kinase - 
MAPK kinase) [62]. It has been shown that CDKL5, as some other members of the 
CMGC group, is capable of autophosphorylating its TEY motif [55,61].  
 
The long C-terminal tail of CDKL5 (from a.a. 298) that does not share homology with other 
human proteins acts as a negative regulator of the catalytic domain and is also involved in the 
regulation of the stability of CDKL5 [55]. Three putative signals, regulating the intra-cellular 
localization of CDKL5, are present in the tail: two nuclear localization signals (NLS) and one 
nuclear export signal (NES), as shown in Fig.3. Lastly, three PxxP sites in the C-terminal tail 
(within 525 a.a. and 781 a.a.) constitute a putative binding site for Src homology 3-domain 













Fig.3 Schematic representation of CDKL5-115 with the functional domains and signatures indicated. In blue 
the catalytic domain with the ATP-binding site and the TEY motif.  In white and red the COOH-terminal tail. 




CDKL5 mutations  
 
Almost 90 different CDKL5 patients have been described so far, harboring a wide range of 
clinical conditions. Data from genetic screenings for CDKL5 in cohorts of patients with 
atypical RTT syndrome show a wide range of pathogenic mutations including missense and 
nonsense mutations, deletions, insertions, aberrant splicing and frameshifts (Fig.4).  
Among almost 75 identified mutations so far, only 5 can be considered as “hot spots” 
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(indicated with an asterisk in Fig.4) [52].  
Missense mutations localize mainly in the catalytic domain, confirming the relevance of the 
kinase activity of CDKL5 for proper neuronal functions, and lead generally to loss of 
funtions. Two missense mutations in the catalytic domain (C152F and R175S) have been 
suggested to interfere with, respectively, phosphotransfer and either kinase activation or 
substrate specificity [61]. On the contrary, truncating mutations occur anywhere in the gene. 
The relevance of the rather uncharacterized C-terminal part of CDKL5 is suggested by the 
fact that many pathogenic alterations involve this region. The C-terminal tail  is, as already 
mentioned, probably involved in regulating the catalytic activity and the subcellular 
localization [52]. 
Regarding the subcellular localization of CDKL5, the protein is present in both the cytoplasm 
and nucleus of expressing cells. Importantly mis-localization of the kinase is evident in both 
the pathogenic derivatives, L879X and R781X, causing the truncation of the very last portion 
of the C-terminus and confining CDKL5 to the cell nucleus. 
Some studies have reported pathogenic duplications of X chromosome regions including 
CDKL5 [52,70] suggesting that also CDKL5 levels must be finely tuned within the brain. 
This is in accordance with the fact that the expression of the kinase is finely regulated in 
developing and mature neurons. 
So far, no clear genotype-phenotype correlation of CDKL5 mutations have been established. 
Some reports, not always confirmed, suggested that mutations in the C-terminal tail originate 
milder clinical pictures than those caused by mutations in the catalytic domain [52]. The 
phenotypic variability of the patients is probably due to the different penetrance of mutations 
[71] and to skewed X-Chromosome inactivation. Weaving et al. [48] reported two genetically 
identical CDKL5-mutated twin girls with a significant discordant phenotype (the first proband 
showed a phenotype overlapping RTT, while her sister showed autistic disorder and mild-to-
moderate intellectual disability); in this particular case, the reason of these different 







Fig.4 All mutations in CDKL5 reported to date. Mutations shown above the CDKL5 gene are deletion and 
frame shift mutations as well as splice variants indicated with cDNA nomenclature. Missense and nonsense 
mutations (fuchsia and black, resp.) are represented with amino acid nomenclature below the CDKL5 gene. ∗: 






Our present knowledge of CDKL5 functions is still rather limited, but first evidences suggest 
the involvement of the kinase in processes related to the regulation of gene expression  and 
neuronal morphogenesis. CDKL5 is present in neurons both in the nucleus and in the cytosol, 
where it interacts with specific proteins. The study of these interactions provide a platform to 
understand the functions of CDKL5, the signaling pathways in which it could be involved 
and, finally, the relationship between CDKL5 mutations and the pathogenesis of Rett 
syndrome. In the nuclear compartment of primary hippocampal neurons (E18, DIV10-12), 
endogenous CDKL5 shows a diffuse staining with brilliant nuclear dots that do not overlap 
with heterochromatic DAPI-positive DNA [63], while the cytosolic CDKL5-immunostaining 
is finely dotted in both the soma and along the dendrites. Similarly, in adult (P21) mouse 
brain the punctate pattern of CDKL5-immunoreactivity is evident in cell bodies, along 
dendrites and in synaptic spines [64]. In the nucleus, clinical and biochemical data suggest 
that CDKL5 belongs to the same molecular pathway as MeCP2, since CDKL5 binds, both in 
vitro and in vivo, and phosphorylates MeCP2 in vitro [59].  Two other nuclear CDKL5-
interactors have also been found, both involved in the regulation of gene expression.  The first 
was DNMT1 (DNA (cytosine-5)-methyltransferase 1), an enzyme that recognizes and 
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methylates hemimethylated CpG after DNA replication. Indeed, it was found that a truncation 
derivative of CDKL5, containing only the catalytic domain, binds and phosphorylates in vitro 
DNMT1 in the N-terminal region in the presence of DNA [65]; further studies are required to 
confirm the interaction in vivo and with a full length kinase. The second nuclear CDKL5-
interacting protein is the SR-family splicing factor, SC35, which co-localizes with CDKL5 in 
the neuronal nuclear speckles both in vitro and in vivo and also co-immunoprecipitates with 
the kinase [66]. Regarding the putative functions of CDKL5 in the nucleus, we can conclude 
that this kinase could represent an important regulator of gene expression via different 
molecular interactions, but so far no bona fide CDKL5-target genes are univocally 
recognized. 
In the cytoplasmic compartment, CDKL5 was recently found to participate in the regulation 
of the excitatory dendritic spine development and dendritic morphogenesis.  The first 
regulatory mechanism involves the molecular interaction between CDKL5 and NGL-1 
(Netrin-G1 Ligand 1), a transmembrane protein localized in the Post Synaptic Density 
compartment (PSD) [64]. NGL-1 specifically interacts with Netrin-G1, a lipid-anchored 
protein related to the netrin family of axon guidance molecules, promoting the early synapse 
formation and subsequent maturation [67].  Among PSD-enriched proteins, the three 
components of the NGL-family (NGL-1, NGL-2 and NGL-3) were identified as CDKL5-
interacting partners. CDKL5, which co-localizes both in vitro and in vivo with PSD95 and 
with excitatory synapse markers (Shank, NR2 and GLUT1), binds and phosphorylates NGL-1 
in vitro and this phosphorylation strengthens the interaction between NGL-1 and PSD95  
[64]. On the other hand, CDKL5 participates in neuronal morphogenesis regulation through 
the interaction with Rac1 (Ras-related C3 botulinum toxin substrate 1), a critical regulator of 
actin remodeling. Accordingly, this small signaling G protein, which is a member of the Rho 
family, appears to regulate cell growth and cytoskeletal reorganization [68]. BDNF 
stimulation enhances the interaction between CDKL5 and Rac1, leading to the effects of 
CDKL5 on neuronal morphogenesis (see below). Furthermore,  CDKL5 was found to co-
localize with F-actin in the peripheral domain of growth cones in cultured neurons at DIV2, 
suggesting that CDKL5 might be involved in regulating the actin cytoskeleton also in this 
compartment [56]. 
Chen et al. [56] recently studied the effects of CDKL5 silencing in rat hippocampal primary 
cultures and reported a decrease in total length of both dendrites and axons (DIV3 neurons 
silenced at DIV0), and a marked reduction in dendritic arborization (DIV8 neurons silenced at 
DIV5). The same data were confirmed in vivo (P4 rats)  when CDKL5 was silenced in 
neuronal progenitors through in utero electroporation at E15.  In these experiments, also the 
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migration of neurons in the cortex showed defects. Migration was not blocked but delayed, 
since neurons devoid of CDKL5 were able to migrate into cortical layers during the first post-
natal days, extending apical dendrites toward the pial surface by P14. The impairment in 
dendritic arborization was not a secondary consequence of the migratory defect because 
similar deficits in arborization were seen using a less effective shRNA construct that had little 
effect on neuronal migration.  
In a recent paper, Ricciardi et al. demonstrated the importance of CDKL5 in the development 
of dendritic spines. Knocking down CDKL5 in mouse primary neuronal cultures increases the 
dendritic protrusion density and alters their morphology: the protrusions are thinner and show 
a filopodia-like configuration. These morphological alterations are associated with a reduction 
in the number of excitatory synapses and synaptophysin puncta. The electrical counterpart is 
represented by a significant decrease of mEPSCs, suggesting an involvement of CDKL5 in 
the regulation of neuronal activity. Confocal images of coronal slices of P11 mouse brain 
after CDKL5-silencing by in-utero electroporation at E13.5 confirms the data in vitro: cortical 
pyramidal neurons showed an increase in the protrusion density along with abnormal 
morphology. In the same neurons also the density of VGLUT-1 puncta, identifying excitatory 
pre-synaptic buttons, was reduced.  
Altogether these data suggest that, since the regulation of dendritic and spine morphogenesis 
is one of the essential target points of synaptic plasticity,  CDKL5, showing a crucial role in 
these processes, could be considered as an interesting new plasticity-related molecule.  
Rett syndrome is characterized by a number of synaptic deficits [69] and the impairment in 
synaptic plasticity could explain, although partially, some clinical features such as motor 
disabilities, the speech absence or the severe cognitive dysfunctions. Interestingly the 
expression of CDKL5 increases during development, correlating with neuronal maturation 
and the formation of new complex synaptic networks in cortical and sub-cortical areas. Other 
molecular processes linked to neuronal activation during synaptic plasticity (transcription and 
post-transcriptional events) could also be regulated by CDKL5 via specific interactions with 
transcriptional regulators and epigenetic factors (MeCP2, DNMT1), or with splicing factors 
(SC35).  
Lastly, to complete this hypothetic overlap between CDKL5-functions and plasticity-related 
processes, we can mention the response of the kinase to specific neuronal stimuli.  In a recent 
publication [63], the sensitivity of CDKL5 to glutamate, the most abundant excitatory 
neurotransmitter, was tested in hippocampal cultured neurons in terms of expression and sub-
cellular localization of the kinase. A rapid exit of CDKL5 from the nucleus, followed by a 
massive proteasome-dependent degradation was observed after glutamate treatment. The 
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meaning of this response remains to be elucidated, but probably the expression levels and the 
sub-cellular localization of the kinase could be related with different roles played by different 
molecular interactions. Interestingly, the kinase-dead K42R-CDKL5 is much less abundant in 
the nucleus than in the cytosol [61], suggesting a link between the kinase activity and its sub-
cellular localization. Other mechanisms, related to unknown signals during development, can 
regulate this nucleocytoplasmic distribution since the abundance of CDKL5 in the nucleus 
increases during development and reaches, in several brain districts of adult mice, almost 50% 
of total CDKL5 levels [54,63].  In the future it would be very interesting to understand better 
the response of CDKL5 to different stimuli and the signaling pathways involved in regulating 











CDKL5 expression during early neuronal activation 
 
As already mentioned, recent biochemical data suggest that CDKL5 is involved in proper 
neuronal functions and in the regulation of dendritic and spine morphogenesis [56,64], but 
very little is known about the molecular pathways regulating its activities in developing and 
mature neurons. It is already known that CDKL5 in neurons is sensitive to specific neuronal 
stimuli, such as glutamate, that regulates the sub-cellular localization and degradation of the 
kinase [63]. Therefore, we decided to investigate the response of CDKL5, in terms of 
transcription, translation, post-translational modifications, and sub-cellular localization to 
neuronal depolarization induced by KCl treatment. We started evaluating the endogenous 
Cdkl5-expression levels in hippocampal primary cultures prepared from E18 mouse embryos 
before and after KCl treatment. Neurons were cultured for 3, 7 and 12 days in vitro (DIV), 
and were exposed for 5 min (minutes) to 50 mM KCl or, as control, to KRH containing 5 mM 
KCl. Neurons were directly collected in Laemmli buffer and Cdkl5-expression was assayed 
by Western blotting (8% SDS-PAGE) using the signal of neuron-specific Class III β-tubulin 
(Tuj1) as internal standard. Moreover, the efficacy of the KCl treatment in activating neurons 
was assessed by the increase in Erk-1/2 phosphorylation using a phospho-specific antibody. 
Interestingly, we found that in KCl treated neurons, Cdkl5-expression was increased 
significantly up to 60% (Fig.5A, B), while other proteins that are known to play essential 
roles in the early phase of neuronal activation (c-Fos, Erk-1 and Erk-2) did not change their 
expression levels during the first 5 min of stimulation (Fig.5A, C, D). In accordance with 
literature, we found an increase in c-fos expression only after 40 min of KCl treatment (data 
not shown).  
In agreement with a recently published article [54], we found that endogenous Cdkl5 levels 
gradually increase with maturation in vitro from DIV3 to DIV12.  Furthermore, KCl 
treatment caused an increase in Cdkl5 protein levels also when DIV3, 7 and 12 hippocampal 
neurons were treated for 5 min. Moreover, similar results were obtained when cortical 
primary neuronal cultures obtained from E18 mouse embryos were treated with KCl (data not 
shown) altogether indicating that the KCl induced increase in Cdkl5 levels does not depend 
on maturation stage and neuronal type. To investigate the mechanisms involved in the KCl-
dependent activation of the Cdkl5-gene, we analyzed the synthesis of the kinase at the 
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transcriptional and translational levels after 5 min stimulation with KCl. For the 
transcriptional response, total RNA was extracted from treated and non-treated hippocampal 
primary cultures (DIV7) and Cdkl5-mRNA levels, along with those of c-fos-mRNA, were 
analyzed by quantitative RT-PCR (qPCR). Both mRNA levels, Cdkl5 and c-fos, were 
significantly increased during early depolarization (+34% and +59% respectively, Fig.5E).  
Since an increase in mRNA content reflects a change in gene transcription and/or a 
modification of mRNA stability, we used actinomycin-D to block RNA pol II activity 
allowing us to analyze whether the increase in Cdkl5 mRNA levels might be due to a KCl 
induced alteration of the mRNA half life. Transcription was inhibited by treating neurons with 
20 µg/ml of actinomycin-D for 30 min whereafter depolarization was obtained by a 5 min 
KCl treatment. No increase in Cdkl5-mRNA and c-fos-mRNA levels were observed, 
suggesting that the KCl-dependent activation of Cdkl5 is mediated by transcriptional 
activation (data not shown).  
A prolonged stability of the kinase might also participate in the observed up-regulation; 
therefore, cultured neurons were treated with cycloheximide (an inhibitor of translation 
elongation) for 30 min before applying KCl; no increase in the level of Cdkl5 expression was 







Fig. 5 Cdkl5 expression is induced during early neuronal depolarization in hippocampal neurons in vitro. 
Hippocampal neurons were isolated from E18 mouse embryos and treated with 50 mM KCl or, as control, KRH 
for 5 min at DIV7. All values are expressed as the average of at least 3 different experiments ± standard error of 
the mean (SEM). The significance was evaluated by Student’s t test and statistical significance was established 
as p < 0.05 (*) or p < 0.01 (**). 
A) Western blot analysis of Cdkl5 and c-fos expression in E18-DIV7 hippocampal neurons treated with KCl as 
indicated. Beta-tubulin III (TUJ1) was used as internal standard.  B) Statistical analysis (t-test, N>3) after 
densitometric quantification (QuantityOne Biorad software). C, D) Western blot analysis of Erk-1/2 expression 
in treated neurons and t-test statistical analysis. E) Cdkl5 and c-fos mRNA levels determined by RT-qPCR 
(N=3). Total RNA was collected from E18-DIV7 hippocampal neurons treated for 5 min with 50 mM KCl and 
subjected to RT-qPCR analysis.  c-fos mRNA levels were used as indicator of neuronal activation, and the 
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expression of Gapdh as internal standard. The statistical analysis was performed by using the “ΔΔCt method” to 
compare relative expression. F) Graphic illustration showing Cdkl5 protein levels in E18-DIV7 hippocampal 
neurons treated for 30 min with 40 µM cycloheximide (CHX) and then exposed to 50 mM KCl for 5 min. No 
increase in the level of Cdkl5 protein levels was found. Statistical analysis (t test, N=3) after densitometric 
analysis of WB (QuantityOne Biorad software).  
 
To validate these results with a different model of neuronal activation, KCl was applied to 
cortical slices. Frontal cortical slices of adult mice (P35-P38) were prepared and maintained 
alive in a solution saturated with 95% oxygen and 5% carbonic anhydride. Depolarization was 
obtained with a perfusion buffer (1 ml/min) containing 30 mM KCl for 5 min [110-112]. 
Cdkl5 levels in depolarized slices were determined by Western blotting and compared with 
those in paired slices perfused for the same time using a low-KCl solution (3 mM). 
Interestingly, an increase in Cdkl5 levels similar to that observed in cultured primary neurons 
could be observed also in this in vivo system (+60%, Fig.6A, 6B).  As before, Erk-1 and Erk-





Fig.6 Cdkl5 expression is induced during early neuronal depolarization in cortical neurons in an ex-vivo 
model. A, C) Western blot analysis showing Cdkl5 and Erk-1/2 protein levels in P35-P38 mouse cortical slices 
treated or not with 30 mM KCl for 5 min. The cortical slices were maintained in a solution with 95% oxygen and 
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5% CO2 for 30 min at 32°C and at 25°C for other 30 min before perfusion with a gassed solution containing 30 
mM KCl for 5 min. The control slices were perfused using a low-KCl (3 mM) gassed solution. Beta-tubulin III 
(TUJ1) was used as internal standard. B, D) Graphic illustration of Cdkl5 and Erk-1/Erk-2 protein expression 
levels in treated and untreated slices (N=3; standard error expressed as SEM; the significance of results was 




Signaling pathway(s) involved in the regulation of CDKL5 expression 
 
In order to characterize the receptors and signaling pathway(s) activated by KCl and leading 
to the observed increase in Cdkl5-expression, we evaluated the activation of the excitatory 
synapses [64] by inhibiting specific molecular targets essential for synaptic transmission. The 
entry of calcium in neurons after glutamatergic transmission activates downstream pathways 
involving PI-3K, PKA, PKC, αCaMKII and MAPKs (mitogen-activated protein kinases) 







Figure 7. Glutamatergic synapse: proposed sequences leading to changes in long term potentiation (LTP). 
Glutamate released from the pre-synaptic membrane binds both AMPA and NMDA receptors, but the NMDA-
Rs remain functionally blocked by magnesium ions. AMPA-Rs conduct mostly sodium ions thereby 
depolarizing the post-synaptic membrane. With sufficient post-synaptic depolarization, magnesium ions are 
released from the NMDA-Rs and calcium ions enter the cell triggering the activation of molecules related to the 
LTP signaling pathways:  PI-3K, PKA, PKC, αCaMKII and ERKs/MAPKs.  
Abbreviations: NMDA, N-methyl D-aspartate; mGlu: Metabotropic glutamate receptors; AMPA, α-amino-3-
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hydroxy-5-methyl-4-isoxazolepropionic acid; αCaMKII, Ca2+/calmodulin-dependent protein kinases II; 
MAPKs/ERKs, Mitogen-activated protein kinases/Extracellular-signal-regulated kinases; PKA, Protein kinase 




To test the involvement of calcium for the KCl mediated Cdkl5 increase, DIV7 hippocampal 
neurons were maintained for 20 min in their medium supplemented with 2 mM EGTA (a 
chelator of calcium ions) before being treated with KCl. As shown in Figure 4, KCl treatment 
does not induce any increase in Cdkl5 levels in neurons treated with EGTA, demonstrating 
that the observed activation of Cdkl5 is calcium dependent. We proceeded analyzing a 
possible involvement of NMDA receptors (Rs), which are key molecules for the influx of 
calcium into the cells [90]. Thus, neurons were pretreated for 30 min with 100 µM AP5, a 
pharmacological antagonist of NMDA-Rs, before the standard KCl activation. Cdkl5 
induction was found to be NMDA-R dependent since no change in Cdkl5 expression was 
observed after AP5 treatment. The importance of NMDA-Rs in the regulation of Cdkl5-
expression in activated neurons was also confirmed by using CNQX, an AMPA channel 
antagonist, since the AMPA-Rs work in the glutamatergic synapse permitting and regulating 
the NMDA-R activation [91]. Cdkl5-expression remained unaltered when DIV7 hippocampal 
neurons were treated with 40 µM CNQX for 30 min before and during the KCl treatment.  
The intracellular signaling cascades activated by calcium influx upon opening of NMDA-Rs 
involve various signaling molecules, protein phosphatases, and protein kinases such as 
mitogen activated protein kinases (MAPKs), the PKA (Protein Kinase A), PI3K etc. [92-99, 
118-122]. The rapid and transient activation of MAPKs and PKA are essential for proper 
induction of long-term potentiation (LTP) [100-105, 113, 114]; indeed, they are associated 
with a specific regulatory pathway that can couple NMDA-R opening to the activation of 
translation initiation factors in the hippocampus, triggering protein synthesis during LTP via 
the MnK1 (mitogen-activated protein kinase-interacting kinase 1) activation and the 
phosphorylation of eIF4E (eukaryotic translation initiation factor 4E) [95, 115] (Fig. 9).  
Therefore, we exposed hippocampal neurons to specific inhibitors of ERK-1/2 (10 µM 
UO126) and PKA (20 µM H89) for 20 and 30 min, respectively, before and during KCl 
treatment. Cdkl5 protein levels remained unaltered upon KCl treatment in the presence of 
these inhibitors (Fig. 8). Similarly, the lack of KCl-induced Cdkl5 increase was also observed 
when the hippocampal neurons were pre-treated with 2 µM wortmannin, a specific PI3K 






Fig. 8. NMDA receptor-dependent signaling pathway(s) are involved in the KCl-mediated increase of 
Cdkl5 expression. Cdkl5 protein levels in E18-DIV7 hippocampal neurons treated with 50 mM KCl for 5 min 
alone or upon pre-treatment with inhibitors of specific signaling pathways (EGTA 2 mM, AP-V 100 µM, CNQX 
40 µM, UO126 10 µM, H89 20 µM). All values are expressed as the average of 3 different experiments ± 
standard error of the mean (SEM). The significance of results was evaluated by Student’s t test and statistical 








Fig.9 The interaction of three major signaling pathways in post-synaptic neurons during LTP, converging 
on the regulation of translation. The influx of calcium through NMDA-Rs or voltage-dependent calcium 
channels (VDCC) can engage signaling cascades that activate MAPKs and αCaMKII. PKA can be activated by 
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beta-adrenergic receptors (β-AR) and by the influx of calcium through NMDA-Rs. The intracellular calcium 
stimulates Ca/CaM (calcium and calmodulin) sensitive adenylyl cyclase increasing cAMP levels. Cytosolic 
cAMP can bind to regulatory subunits of PKA holoenzymes causing the release of the free catalytic subunits that 
translocate to the nucleus and phosphorylate the transcription factor CREB. αCaMKII, MAPKs and PKA are all 
required for the induction of LTP. 
The activation of MAPKs and PKA are both required for the activation of MnK1-eIF4E, involved in activity 
dependent protein synthesis; for exemple, MAPKs are required for an increase in αCaMKII levels produced by 
LTP-inducing stimulation.  
Abbreviations: NMDA, N-methyl D-aspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; 
VDCC, voltage gated calcium channels; AC, adenylyl cyclase; PP2b, protein phosphatase 2b (calcineurin); I-
1●P, phosphorylated protein phosphatase inhibitor-1; Ras, Rap1, Raf-1, B-Raf, and MAPK/ERK kinase (MEK) 
are all components of the MAPKs cascade; αCaMKII, Ca2+/calmodulin-dependent protein kinases II; 
MAPKs/ERKs,  Mitogen-activated protein kinases/Extracellular-signal-regulated kinases; PKA, Protein kinase 




The role of NMDA-Rs and PKA in the regulation of Cdkl5 expression was confirmed by 
using specific activators of these molecules. DIV7 hippocampal neurons were stimulated for 5 
min with N-Methyl-D-aspartate (50 µM), an agonist of NMDA-Rs, or forskolin (100 µM), an 
adenylyl cyclase activator that activates PKA by increasing cAMP levels. These results 
confirmed the importance of NMDA and PKA for the increase in Cdkl5-expression (Fig. 
10A, 10B). It is also interesting to consider the response of Cdkl5 in cultured hippocampal 
neurons treated with BDNF (brain-derived neurotrophic factor), a neurotrophic factor that is 
a member of the "neurotrophin” family of growth factors. Interestingly, BDNF treatment of 
DIV12 neurons, when the TrkB receptors are likely to be expressed, caused an increase in 
Cdkl5 levels (Fig. 11A, 11B; N=2) [105,106,183]. To conclude, these results show that Cdkl5 









Fig.10 Cdkl5 expression is induced by activation of NMDA-Rs and PKA. 
A) Immunoblot analysis of Cdkl5 expression in unstimulated DIV7 hippocampal neurons or in neurons treated 
for 5 min with 100 µM forskolin or with 50 µM NMDA.    
B) Graphic illustration of Cdkl5 levels in treated versus untreated cells. Cdkl5 protein levels were normalized to 
β-tubulin III (TUJ1). All values are expressed as the average of different experiments (NMDA N=3; forskolin 






Fig.11 BDNF induces Cdkl5 expression in mature neurons. A) Western blot analysis of Cdkl5 expression in 
DIV12 hippocampal neurons after 5 min of treatment with 50 µg/ml BDNF.  B) Graph showing Cdkl5 levels 
normalized to those of TUJ1 in neurons treated or not with BDNF. The values are expressed as the average of 2 




CDKL5 expression during the late phase of neuronal activation 
 
Having demonstrated that Cdkl5 gets activated soon after neuronal depolarization, we decided 
to evaluate what happens to its expression upon prolonged stimulation. Thus, we performed a 
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time-course analysis addressing the expression levels of the kinase during KCl-stimulation of 
DIV3 and DIV7 hippocampal neurons. Cells were directly collected in Laemmli buffer at 
different time points after KCl stimulation (5, 20, 40 min, 1 and 3 hrs) and Cdkl5 expression 
assayed by Western blotting. Interestingly, we found that in both cases a prolonged KCl 
treatment leads to a significant down-regulation of the expression of the kinase, leading to its 
disappearance after 3 hours of stimulation. However, a different kinetics can be observed 
depending on the neuronal maturation stage. Indeed, as already reported above, in more 
mature neurons (DIV7; Fig. 12A, 12B) Cdkl5 levels increase soon after KCl treatment (5 
min) and then progressively diminish, becoming indetectable at 3 hrs. Conversely, in DIV3 
neurons, Cdkl5 levels, which are lower in comparison to DIV7 neurons, increase with the 
same kinetics (5 min) but remain elevated for much longer; indeed, a significant reduction in 
the Cdkl5 signal appears only at 1 hour and a faint signal is visible even 3 hrs after KCl 
administration (Fig. 12C, 12D). The half-life of Cdkl5 (expressed exogenously in cell lines 
though) has been estimated to almost 6 hrs [53], we therefore reasoned that the observed 
down-regulation might probably be mediated by an active proteolysis of Cdkl5. The 
degradation of Cdkl5 could also be observed in frontal cortical slices of adult mice after 
prolonged KCl stimulation (1 hour) in comparison with control slices, while Erk-1/2 levels 







Fig.12 A prolonged KCl treatment down-regulates Cdkl5 expression in hippocampal neurons and in 
cortical slices. A,C) Western blot analysis of Cdkl5 expression in DIV7 (A) and DIV3 (C) hippocampal neurons 
after 5, 20, 40, 60 and 180 min of 55 mM KCl treatment. B, D) Statistical analyses of Cdkl5 expression in DIV7 
(B), DIV3 (D) hippocampal neurons. E) Western blot showing Cdkl5 and Erk-1/2 levels in cortical slices after 1 
hour of perfusion with 30 mM KCl solution (lane b) or with buffer alone (lane a). F) Statistical analysis of (E); 
expression levels of Cdkl5 (lane b), Erk-1 (lane c) and Erk-2 (lane d) in comparison with the control level in not 
treated slices (lane a). All values are expressed as the average of 3 different experiments ± standard error of the 
mean (SEM). The results were evaluated by Student’s t test and the statistical significance was established as p < 




To determine the mechanisms by which Cdkl5 gets degraded during the late phase of 
neuronal depolarization, cultured hippocampal neurons (DIV3 or DIV7) were treated with 50 
µM MG132, an inhibitor of proteasomal activity, for 3 hours before stimulating with KCl. In 
DIV7 hippocampal neurons, Cdkl5 degradation was partially prevented by the presence of 
MG132 (Fig. 13A). Indeed, by quantifying three independent experiments we found that, in 
the absence of MG132, 80% of Cdkl5 disappears upon the prolonged KCl stimulation, 
whereas by inhibiting proteasome degradation, more than 50% of Cdkl5 resists to the KCl 
treatment (Fig. 13B). It is worth noting that MG132 per se led to a significant increase in 
Cdkl5 levels, indicating that, in “mature” neurons, the kinase is a constitutive target of the 






Fig.13 Cdkl5 turnover is regulated by the proteasome activity in DIV7 hippocampal neurons. A) Western 
blot analysis of Cdkl5 expression after 3 hours of treatment with 55 mM KCl preceded or not by a treatment of 3 
hours with 50 µM MG132 (lanes d and c, respectively). As control, neurons were treated for 6 hours exclusively 
with MG132 (lane b) and compared with non-treated neurons (lane a). B) Statistical analysis; the letters below 
the bars correspond to panel A. All values are expressed as the average of 3 different experiments ± standard 
error of the mean (SEM). The significance of the results was evaluated by Student’s t test; statistical significance 




On the contrary, in immature neurons (DIV3), Cdkl5 levels are not regulated by the 
proteasome; indeed, its turn over, both in unstimulated or long-lasting depolarized conditions 
appear insensitive to MG132 (Fig. 14A, 14B). Therefore, summarizing the obtained results 
we suggest that during neuronal maturation the proteasome becomes one of the factors 
controlling Cdkl5 levels. The fact that 50% of the proteins gets degraded even when the 
proteasome has been inhibited suggests that in our experimental conditions the turnover of the 
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Fig.14 In immature hippocampal neurons Cdkl5 protein levels are not affected by the proteasome. A) 
Western blot analysis of Cdkl5 expression in control neurons (lane a) and after 6 hours of treatment with 50 µM 
MG132 (lane c), or 3 hours of treatment with 55 mM KCl pretreated or not for 3 hrs with MG132 (lane d and b). 
B) Statistical analysis (t-test, N=3) after W.B. densitometry (QuantityOne Biorad software). The lanes are the 





Considering that a previous publication from our laboratory demonstrated that upon glutamate 
stimulation CDKL5 exits the nuclear compartment and then gets degraded [63], we evaluated 
the subcellular localization of endogenous Cdkl5 in non-treated and KCl-treated hippocampal 
neurons. However, no difference in the kinase localization was observed in any tested time 




Post-translational modification of CDKL5 during neuronal depolarization 
 
While depicting the reactivity of Cdkl5 upon depolarization at different time points, we 
noticed that Cdkl5 was showing a faster electrophoretic mobility when neurons were treated 
with KCl for 20 min (Fig.8A). We reasoned that different levels of Cdkl5 phosphorylation 
might cause the observed change in mobility.  
Importantly, few publications have already suggested a regulation of CDKL5 
phosphorylation. In particular, it has been demonstrated that CDKL5, as some other kinases 
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belonging to the CMGC group, is capable of auto-phosphorylating its TEY motif [55,61]; 
however, the timing and duration of this phosphorylation, as well as the specific stimuli 
driving it and its functional meanings remain unknown. Of possible relevance, it is interesting 
to observe that CDKL5 shows some similarity, including the presence of the TEY motif, with 
the extracellular signal-regulated kinases (ERKs); in these kinases, the dual phosphorylation 
of the TEY motif is generally required for the activation of their catalytic site [108,117]. 
However, in ERK-7, a member of the family, this motif is constitutively phosphorylated by 
auto-phosphorylation and the kinase is constitutively activated [109]. Interestingly, Chen et 
al. have recently reported a transient increase in DIV5 rat cultured cortical neurons of CDKL5 
threonine phosphorylation, showing the highest level 5 min after BDNF stimulation; these 
data indicate the presence of rapid post-translational modifications of the kinase during 
neuronal activation [56].  
In order to investigate whether the observed change in Cdkl5 mobility is caused by its 
dephosphorylation, we performed an in vitro dephosphorylation assay. DIV7 hippocampal 
cultured neurons were collected directly in lysis buffer and the lysate was incubated with 
Lambda Protein Phosphatase (presenting activity towards phosphorylated serine, threonine 
and tyrosine residues; PPase).  Samples were run on a 7% SDS-PAGE followed by 
immunoblotting. After Lambda PPase treatment, a “fast-migrating” band was detected using 
the anti-CDKL5 specific antibody, therefore corresponding to a dephosphorylated form of the 
kinase (Fig. 15A). These data suggest that in non-stimulated mouse hippocampal neurons, 
Cdkl5 is constitutively phosphorylated. 
We proceeded by comparing the electrophoretic mobility of Cdkl5 after prolonged KCl 
treatment to that obtained by dephosphorylation. Thus, DIV7 hippocampal neurons were 
treated with KCl for 40 min and Cdkl5 migration analyzed by Western blotting. Interestingly, 
after prolonged depolarization Cdkl5 presents the same “fast-migrating band” as obtained 
with Lambda PPase treatment (Fig. 15B). These data suggest a KCl-dependent loss of Cdkl5-
phosphorylation. Immunofluorescence experiments of KCl treated neurons showed that the 
overall ratio of Cdkl5 remains constant between the nucleus and the soma suggesting that the 







Fig.15 CDKL5 is dephosphorylated during the late phase of neuronal depolarization. A) DIV7 
hippocampal neurons were collected in lysis buffer and treated with Lambda PPase as indicated. The samples 
were separated by 7% SDS-PAGE (acrylamide/bisacrylamide 77/1) and analyzed by Western blotting. The 
mobility of Cdkl5 is increased upon PPase treatment compared to control non-treated neurons (lanes b and c, 
respectively). Mock control: the extract was incubated as for lane b (3h, 30°C, Lambda PPase, buffer) but 
omitting the enzyme (lane c). B) After KCl-treatment (55 mM 40 min) of DIV7 hippocampal neurons, Cdkl5 
migration is identical to that of the PPase treated sample (lanes c and b, respectively). Control: non-treated DIV7 
neurons (lane a). C) Cdkl5 maintains its subcellular distribution after 40 min of KCl treatment. Representative 
immunofluorescence assays, using antibodies against CDKL5 (red) or DAPI staining (blue), of unstimulated 




By analyzing CDKL5 mobility at different time points after KCl stimulation, we could 
observe that dephosphorylation starts already at 5 min of depolarization, when a doublet can 
be recognized (shown by arrows, Fig. 16A) and becomes more pronounced at 20 min of KCl-
treatment (Fig. 16B). It is interesting to note that when tested in younger hippocampal 
neurons (DIV3), the KCl-dependent dephosphorylation of Cdkl5 was not apparent (Fig. 16C), 
suggesting that the mechanisms related to the dephosphorylation of Cdkl5 depends on 
neuronal maturation. We hypothesize that a relationship exists in DIV7 cultured hippocampal 
neurons between Cdkl5 dephosphorylation and the subsequent proteasome-dependent 
degradation of the kinase, both of which are absent in younger neurons (DIV3).  
To summarize, CDKL5 appears to be constitutively phosphorylated in cultured mouse 
hippocampal neurons and is sensitive to KCl-treatment in terms of expression, post-






Fig.16 Cdkl5 dephosphorylation starts early after depolarization. A) DIV7 hippocampal neurons were 
treated or not with 55 mM KCl for 5 min and Cdkl5 migration analyzed by 7% SDS-PAGE followed by Western 
blotting. Arrows indicate the slow and fast migrating bands corresponding to phosphorylated and 
dephosphorylated Cdkl5 isoforms. B) The dephosphorylation of Cdkl5, hardly detectable after 5 min of 
depolarization, proceeds and becomes clearly visible after 20 min. C) Cdkl5 is not dephosphorylated in DIV3 
hippocampal neurons when treated with 55 mM KCl for 20, 40 and 60 min (lanes b,c,d). The height of the band 




The phosphatases PP1/PP2A regulate the overall phosphorylation state of 
CDKL5 
 
To identify the phosphatase(s) involved in Cdkl5 dephosphorylation, we treated DIV7 
hippocampal neurons with specific inhibitors against tyrosin phosphatases and the 
serine/threonine phosphatases PP1/PP2A (sodium orthovanadate and okadaic acid, 
respectively) before treating with KCl. Whereas treatment with sodium orthovanadate 
(Na3VO4 for 1 hour) did not inhibit Cdkl5 dephosphorylation (Fig. 17A), the administration 
of okadaic acid for 45 min (O.A.) revealed three important features (Fig. 17B): 
 
a) in unstimulated DIV7 hippocampal neurons,  the state of Cdkl5 phosphorylation  is 
influenced by the activity of PP1/PP2A phosphatases. Indeed, a retardation of Cdkl5 
migration is evident in DIV7 hippocampal neurons treated with okadaic acid when compared 
to untreated neurons (lanes c and d, respectively).  This band probably corresponds to a 
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“hyper-phosphorylated” form of Cdkl5 or to another phosphorylation dependent post-
translationally modified isoform of the kinase. 
 
b) the KCl-induced dephosphorylation, observed after 20 min treatment, is blocked by 
PP1/PP2A inhibitors (lanes e and f). We speculate that PP1/PP2A might be directly or 
indirectly involved. The basal conformation of Cdkl5 in resting neurons, regulated by these 
phosphatases, might represent a necessary condition for the intervention of other 
phosphatases. Furthermore, since in depolarized neurons treated with OA we could not detect 
any band corresponding to the slowest migrating band (lanes c and f), we speculate that other 
phosphatases are involved in this regulation and/or that a cross-talk between post-translational 
modifications exist, influencing the overall state of phosphorylation.  
 
c) exploiting a long electrophoresis, a doublet of Cdkl5 becomes visible also after 5 min 
of KCl treatment that differs from the bands observed after 20 min of KCl treatment (compare 
lanes b and e). This suggests, once again, that a complex pattern of post-translational 
modifications occur on Cdkl5 upon specific stimuli. This double-band is also sensitive to 






Fig. 17 The phosphatases PP1A/PP2A alter Cdkl5 phosphorylation during neuronal depolarization.  
A) The KCl dependent dephosphorylation of Cdkl5 is not mediated by tyrosine phosphatases. Immunoblotting of 
DIV7 hippocampal neurons (lane a) treated as indicated with 1 mM Na3VO4 for 1h before the KCl-dependent 
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depolarization (20 min; lanes b,c).  
B) DIV7 hippocampal neurons were treated as indicated with 1 µM okadaic acid (O.A.) for 45 min and KCl for 
the indicated time points. Cdkl5 migration was analyzed by Western blotting after separation of total extracts on 
7% SDS-PAGE. Arrow-heads indicate the fast and slow migrating Cdkl5 isoforms.  
DIV7 hippocampal neurons treated with okadaic acid compared to untreated neurons (lanes c and d, 
respectively).   
The KCl-induced dephosphorylation, observed after 20 min treatment (lane e), is blocked by PP1/PP2A 
inhibitors (f).  





Summarizing the presented data concerning a direct or indirect involvement of PP1/PP2A in 
the regulation of Cdkl5 phosphorylation, we propose the following model (Fig. 18): 
 
i) in non treated neurons, the basal level of Cdkl5 phosphorylation is affected by a 
constitutive action of PP1/PP2A; 
 
ii)  soon after neuronal depolarization, the levels of Cdkl5 phosphorylation decrease 
depending directly or indirectly on PP1/PP2A; 
 
iii) upon sustained depolarization, Cdkl5 gets extensively dephosphorylated. This 








Fig.18 Schematic model of the cross-talk between Cdkl5 phosphroylation and degradation in depolarized 
hippocampal neurons. Our data suggest the presence of distinct Cdkl5 isoforms in hippocampal neurons: 
a. a “hyperphosphorylated form” that is undetectable without inhibiting PP1/PP2A phosphatases; probably, it 
represents a very labile state of Cdkl5 appearing soon after synthesis or depending on stimuli that still remain 
to be discovered; 
b. the “basal” form of Cdkl5, carrying at least one phosphate group, in unstimulated neurons; 
c. the “modified form” of Cdkl5  appears soon after depolarization and is probably characterized by a reduction 
of its phosphorylation state; however, at least one phosphate group is bound to the kinase; 
d. the “dephosphorylated form” of Cdkl5. Prolonged depolarization leads to a dephosphorylated form of Cdkl5 




Is CDKL5 involved in the regulation of genes associated to the early 
neuronal activation?  
 
Considering that CDKL5 is an interactor of molecules related to the regulation of Immediate 
Early Genes expression, like MeCP2 [30, 41, 150] or DNMT1 [65, 297, 298], we decided to 
investigate whether Cdkl5 affects gene expression during neuronal activation. In particular, 
we started focusing on transcription during the first 5 min of KCl-treatment, when Cdkl5 
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expression is up-regulated. Indeed, the transcriptional regulation of the iEGs (immediate 
Early Genes) results from the activation of pre-existing transcription factors and does not 
require protein synthesis [295, 296]. 
We used RT2 Profiler PCR Arrays to obtain the transcription profiles of 84 immediate early 
genes (iEG; listed in Fig. 19C) involved in synaptic plasticity, testing their expression in 
DIV7 control and Cdkl5-silenced hippocampal neurons before and after KCl treatment. To 
down-regulate Cdkl5-expression, DIV0 hippocampal neurons were infected with recombinant 
lentiviral particles produced using the pLentiLox 3.7 GFP plasmid and expressing a short-
hairpin sequence against mouse Cdkl5-mRNA (shCdkl5). Similarly, DIV0 hippocampal 
neurons were infected with a control lentivirus carrying a short hairpin against the β-
galactosidase-mRNA (shLacz). The efficient silencing of Cdkl5 was verified by Western 
blotting (Fig. 19A). The mRNA-expression levels were monitored by RT-qPCR following the 
indications of "RT2 profiler PCR Array Handbook" (QIAGEN), as described in 
“Experimental procedures”. The ΔCt (Ct of iEGs - Ct of housekeeping genes) of 2-3 
independent measurements was mediated and then ΔΔCt (Average ΔCt after KCl treatment - 
Average ΔCt in non treated neurons) was calculated. The Ct of 5 housekeeping genes was 
averaged and used as internal standard, as indicated by the manufacturers ("RT2 Profiler PCR 
Array PAMM-126ZA", QIAGEN).  
An increase (p≤0,05; N=3) in the expression of some iEGs was evident after 5 min KCl 
treatment of control neurons: Akt1 (+20%), Egr1 (+30%), Grm2 (+45%), Rela (+10%), 
Timp1 (+60%) etc. (data not shown). In Cdkl5-silenced neurons, the expression of the same 
genes was similarly increased upon KCl treatment, while the induction of Timp1-gene (Fig. 
19B) (tissue inhibitor of metalloproteinases) was inhibited, suggesting a role of Cdkl5 in 
regulating the expression of this gene, which is involved in the synaptic mechanisms 
underlying learning and memory [116].  
In the future, it will be interesting to confirm these preliminary data and to understand the role 





Fig.19 KCl dependent induction of transcription is altered of neurons devoid of Cdkl5.   A) Western blot of 
Cdkl5 and GFP from DIV7 hippocampal neurons infected at DIV0 with lentiviral particles expressing GFP and a 
shRNA against Cdkl5 (shCdkl5) (lanes c, d) or β-galactosidase (shLacz) (lanes a, b). At DIV7 the neurons were 
treated with KCl for 5 min (lanes b, d) and the expression of Cdkl5 was compared to neurons at basal conditions 
(lanes a, c). The signal of TUJ1 is used as loading control. B) Expression levels of Timp-mRNA in neurons 
expressing Sh-Lacz (lane b)  or shCdkl5 (lane c) treated for 5 min with KCl. The increase of expression in 
control ShLacz neurons (blue bar) is significant (p≤0,05; N=3) and has been compared with 1, the value of the 
expression of the relative gene in non KCl-treated neurons (lane a). In Cdkl5-silenced neurons, the expression of 








Rett syndrome is a postnatal progressive neurodevelopmental disorder that manifests in girls 
during early childhood. Its typical form is characterized by the appearance of 
neurodevelopmental arrest and regression, after a period of apparent normal psychophysical 
development up to 6–18 months of age. As the syndrome progresses, patients lose purposeful 
use of their hands and develop stereotypic hand movements. Loss of language and social 
skills, irritability, breathing anomalies and autistic features become apparent during this 
period of infantile life and will persist throughout adulthood. The severe mental retardation 
and the neurologic malfunctioning prevent patients from leading an independent social life.  
Mutations in the MECP2-gene are associated to the classical form of Rett syndrome [3, 14]. 
MeCP2 is a nuclear protein that binds methylated DNA and recruits histone deacetylases and 
co-repressor complexes to suppress transcription. It belongs to the MBD family of proteins 
involved in the epigenetic regulation of gene-expression [27, 30]. MeCP2 is widely expressed 
but is significantly more abundant in brain, primarily in mature postmigratory neurons [3, 26, 
33, 240]. Its expression in humans increases during the late fetal stage and in infancy [241]. 
Recently, new roles of MeCP2 as a transcriptional activator [30] and a splicing modulator [32, 
230] have also been described. Interestingly, it has been proposed that in neurons MeCP2 
could be considered a global chromatin structure regulator, since its abundance in nuclei is 
similar to one molecule every second nucleosome and its deficiency results in alterations of 
histone acetylation and doubling of histone H1 levels [33]. The role of MeCP2 in the 
regulation of chromatin structure could explain its putative involvement in the suppression of 
transcriptional noise [33] and in the inhibition of Long interspersed nuclear elements-1 
transcription [226]. 
Recently MeCP2 has been described as having a role in the regulation of dendritic 
arborization and spine morphogenesis. Indeed, membrane depolarization triggers MeCP2 
phosphorylation at serine 421, allowing transcription of BDNF [28, 38]. It was demonstrated 
that MeCP2 S421 phosphorylation has a role in chromatin remodeling during neuronal 
activity and synapse development [35]. Furthermore, MeCP2 regulates the strength of 
synaptic response in hippocampal neurons by promoting the formation of glutamatergic 
synapses during early postnatal development [34]. During morphological differentiation of 
neurons and in adult stage, MeCP2 is involved in the regulation of dendritic arborization and 
dendritic spine density and regulates the expression of several synaptic proteins, including 
α/β CaMKII, AMPA, and NMDA receptors [242, 244, 245]. Mouse models have shown that 
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a phenotype similar to that of RTT syndrome can be caused by dysregulation in the 
expression of MeCP2 (underexpression or overexpression), confirming prior studies showing 
that either loss or doubling of MeCP2 results in postnatal neurodevelopmental disorders [34, 
227-229, 244]. 
Atypical forms of Rett syndrome that deviate from the typical clinical presentation have been 
recognized since 1985 when a girl with infantile spasms and RTT-like features was described 
(Hanefeld variant). The atypical presentations of RTT are very different, and vary from 
milder phenotypes such as the “preserved speech variant” to more severe manifestations, such 
as the “congenital form” and the Hanefeld variant, with onset of intractable seizures before 
the age of 6 months [3]. The rare disorder Hanefeld variant was demonstrated related with 
mutations in the X-linked gene cyclin-dependent kinase like 5 (CDKL5). Mutations in the 
CDKL5 gene have also been involved in a wider range of phenotypes including West 
syndrome, mental retardation and autism. In general, CDKL5-mutations are associated to the 
following clinical features: the onset of intractable seizures during the first months of life, 
infantile spasms and severe developmental delay and hypotonia [49, 231]. The product of 
CDKL5 is a serine/threonine kinase that belongs to the CMGC family (named after the initials 
of some members: cyclin-dependent kinases, mitogen-activated protein kinases, glycogen 
synthase kinases and CDK-like kinases). Its catalytic domain, at the N-terminus, shares high 
homology with that of MAPK and CDK family members, while its long C-terminal tail does 
not share homology with other proteins. CDKL5 is a widely distributed protein expressed in a 
lot of peripheral districts, but highest levels are found in brain, particularly in the forebrain 
[50, 52, 53]. At the cellular level, the kinase is highly expressed in neurons, both in nucleus 
and in cytoplasm, whereas very low levels are present in glia. Similarly to MAPKs, the 
cytoplasmic form of CDKL5 is expressed in dendrites and somas of cortical and hippocampal 
neurons, a localization that suggests a role in postsynaptic functions [63, 305]. In non-
neuronal cell lines the kinase shows a constitutive shuttling between the cytoplasm and the 
nucleus through an active nuclear export mechanism utilizing a signal in its C-terminal tail 
[41, 54, 56, 61, 63]. During development, the relative concentration of CDKL5 in the nuclear 
and cytoplasmic compartments of neurons varies (with an increase in the nuclear 
subpopulation during maturation) [54], as well as the expression levels in different brain 
areas. High expression levels were detected in the entorhinal cortex, in the hippocampus and 
in the most superficial cortical layers, involved in the intercortical connectivity, suggesting an 











Fig.20 Cdkl5 expression patterning in the adult male mouse brain (C57BL/6J, postnatal day 56). Each Nissl-
stained section is coupled by a quantitative in situ hybridization screening at different sectioning levels. The 
color bar in (a) might be used to follow transcription level intensity. (b), (c), (d), (e), (f), and (g) are 
representative of different brain levels, therefore, different brain areas.  
Abbreviations: cg (cingulated cortex), st (striatum), pc (piriform cortex), hyp (hypothalamus), ec (entorhinal 
cortex), dg (dentate gyrus), ca1, 2, 3 (hippocampal CA fields), vta (ventral tegmental area), gn (geniculate 




The expression of CDKL5 in brain is generally induced during the late phase of pre-natal 
neuronal development and the early post-natal stage, suggesting an involvement of the kinase 
in the formation and in the maturation of dendritic branches and synapses [54]. Accordingly, 
it has been demonstrated that CDKL5 is a critical regulator of neuronal morphogenesis, 
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neurite growth and dendritic arborization [56]. The cytoplasmic localization of CDKL5 and 
its catalytic activities are essential for the kinase to acquire its functions [56]. Furthermore, in 
the cytosol, CDKL5 phosphorylates NGL-1 (Netrin-G1 Ligand 1), a transmembrane protein 
interacting with Netrin-G1, a regulator of the early synapse formation and subsequent 
maturation [67].  
In spite of the clear importance of CDKL5 for the central nervous system, the exact functions 
exerted by this kinase and its regulatory mechanisms remain mainly unknown. In the nucleus, 
CDKL5 binds MeCP2 and is certainly able to phosphorylate it in vitro [55, 59]; it remains to 
be demonstrated whether in vivo CDKL5 is involved in MeCP2 and Dnmt1 (DNA 
methyltransferase I) phosphorylation [65]. Furthermore, in the nucleus CDKL5 colocalizes 
with nuclear speckles and is probably involved in the regulation of mRNA splicing [66]. 
As mentioned, the levels of CDKL5 and its sub-cellular distribution gets modified during 
neuronal activation. A recent article from our group suggested that the expression and 
subcellular distribution of Cdkl5 appears tightly regulated in mouse hippocampal neurons by 
exposure to glutamate, the most abundant excitatory neurotransmitter in brain. Indeed, a 
glutamate bath induces a rapid exit from the nucleus (through an active nuclear export system, 
mainly occurring in glutamatergic neurons) and a massive proteasome-dependent degradation 
of the kinase [63]. The meaning of this response remains to be elucidated; it was speculated 
that CDKL5 could have different roles in the cytosol and in the nucleus during neuronal 
activation and that different stimuli could regulate its sub-cellular distribution. Furthermore, 
CDKL5 phosphorylation is sensitive to neuronal activation; indeed, in rat cortical cultures 
treated with BDNF for 5 min (minutes), the activation of the TrkB receptor leads to the 
phosphorylation of a CDKL5 threonine residue [56]. The intra-cellular mechanisms involved 
in the response of CDKL5 to the neuronal activation are not known hitherto; it has been 
shown that CDKL5 is capable of autophosphorylating its TEY motif [3, 55, 61] but according 
to the primary structure it is highly possible that CDKL5 contains a lot of phosphorylation-
sites and many kinases or phosphatases could be involved in the post-translational 
modification of CDKL5. Accordingly, proteomic approaches, aimed at revealing in HeLa 
cells phosphoproteins related to the cell-cycle, identified the presence of 14 sites of 
phosphorylation in human CDKL5 (S306, S375, S377, S407, S476, S526, T528, S543, S646, 
S681, S720, S726, S761); in particular, S646 and S761 were found phosphorylated in mitosis 
[337], whereas S407 in G phase [338]. Furthermore, one site of phosphorylation was 
identified in tyrosine-171, belonging to the TEY motif [337]. 
Considering all above, during my Ph.D. activity I decided to start characterizing mechanisms 
that might regulate CDKL5 expression and subcellular localization in murine primary 
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cortical/hippocampal neurons and in cortical slices using KCl-bath as a depolarizing agent 
mimicking the KCl-LTP (Long Term Potentiation) model [307, 356-362]. To better 
understand our results and their interpretation, let me discuss what I consider relevant 
information about LTP and LTD (Long Term Depression) in culture.  
KCl depolarization-induced LTP (KCl-LTP or Chemical-LTP) is an electrophysiological 
model of induction of synaptic potentiation in cultured neurons in which a brief 
depolarization (application of 90 mM KCl: 3 x 1 second) is used to induce an increase in 
synaptic activity in neurons; as a consequence NMDARs are activated by the release of 
endogenous L-glutamate.  
The advantage of studying dissociated neurons cultures consists in the possibility of rendering 
more accessible single synapses and evaluating the activity-related mechanisms during the 
initial steps of synaptic maturation. We focused our attention on DIV3 and DIV7 since 
significant changes in synaptic maturity occur between these two stages. In a recent 
publication, Sohya et al. reported opposite effects of KCl-dependent depolarization on spine 
morphology of rat hippocampal cultured neurons at different stages of maturation, 
demonstrating that high KCl induces synaptogenesis early in development (DIV3) but not 
later (DIV6) [187]. Interestingly, in E15 mouse primary cortical neurons the expression of 
PSD-95, a protein belonging to a multi-protein complex  important in positioning signaling 
molecules for induction of LTP and LTD, starts to be detectable only at DIV7 and shows a 
progressive increase in its levels during synaptic maturation [339, 340].  
ERKs have different functions in the nucleus, where they regulate activity-dependent 
transcription [301, 305] and in the cytoplasm, where they promote synaptic transmission and 
filopodia formation by phosphorylating ion channels [300, 302]. In addition, ERKs are 
activated in the hippocampus following convulsions [300, 301, 305; in vitro models of 
epilepsy using long exposure to KCl: 308, 311]. Other protein kinase cascades are required in 
the induction of the early phase of LTP in the CA1 area [317], subsequently to the stimulation 
of NMDA-Rs [305]; indeed the induction of LTP is blocked by general inhibitors of ser/thr 
protein kinases or tyrosine kinases [317]; accordingly it is well-known that a SRC-dependent 
tyrosine-phosphorylation of NR2B starts within 1-5 min after LTP induction [305, 315, 317]. 
In our experiment, we interpret the observed KCl-induced MAPKs activation (both at DIV3, 
when precocious neuronal processes leading to the synapse formation are activated [184-186], 
and DIV7/DIV12, when the synapses are getting matured) as a sign of neuronal  LTP-related 
processes induced by depolarization. We verified the KCl-induced neuronal depolarization 
following Erk-1/2 activation with an antibody detecting the phosphorylated form of these 
kinases. In 1997, English and Sweatt demonstrated that the induction of LTP in the CA1 
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region of hippocampus activates the ERKs, whereas, a selective inhibition of the MAPKs 
cascade markedly attenuates the induction of LTP, without affecting basal NMDA-Rs-
mediated transmission [113, 300, 302, 305, 326, 331]. NMDA-Rs stimulation in response to 
LTP-inducing high frequency stimulation leads to ERK-2 phosphorylation on tyrosine 42 
after only 2 min (LTP, induced in “artificial” models by extremely brief patterns of afferent 
stimulation, reaches a peak within 30-60 seconds and then declines over time) [299-305]; the 
maximal activation of ERKs occurs within 5 min [302], followed by a slight decrease. Indeed, 
ERKs activation remains observable for at least 2 hours of KCl-bath [301]. In such a 
prolonged KCl treatment (in our conditions up to 3 hours), the onset of processes of 
saturation/resource depletion or active homeostatic regulation might occur [363]. Generally, 
as described in different models, the induction of E-LTP starts soon after the stimulation 
[316] and 2 to 4 hours are required to transit from the Early to the Late phase of LTP [273, 
274, 316], the transcription- and translation-dependent phase that lasts many hours [317, 343]. 
The decline may be due to a naturally occurring activity-dependent LTD (“Long Term 
Depression”) rather than a strictly time-dependent decay [269, 271]. LTD is a form of 
synaptic plasticity [301] important during the activity-dependent “selection” of neuronal 
circuitry; it has been hypothesized that LTP may be responsible for memory formation, while 
LTD may be involved in active suppression of pre-established memory [301]. Experiments in 
vitro and in vivo demonstrated in the rat amygdala the correlation between the induction of 
LTD and a reduced degree of MAPKs-phosphorylation [324]. An increase in post-synaptic 
calcium probably to levels below those necessary to induce LTP is one condition to induce 
LTD. 
Hippocampal LTP is one of the most studied models of synaptic plasticity since its first 
demonstration through high frequency stimulation of afferent nerve fibers [276, 279]. The 
interest for LTP is due to the close parallels between this molecular mechanism and the 
persistence of hippocampus-dependent memory [274]. The most studied form of LTP 
develops through the activation of NMDARs and the consequent increase in AMPARs 
expression at the post-synaptic membrane [275]. The rapid transient depolarization in KCl-
LTP models is due to AMPARs expression on the neuronal surface and is given by an 
increase in mEPSC frequency [270, 278].  
LTP and LTD are both models of neuronal activity proposed after electrophysiological 
studies, using respectively high- or low- frequency stimulations; thus, it is difficult to follow a 
parallel model of activation in KCl-induced depolarized neuronal cultures. In these 
conditions, in fact, we do not know “if” and “when” a prolonged exposure to KCl saturates 
the responsivity of the cell. However, some elements could be considered  good indicators of 
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LTP and LTD, such as the MAPKs phosphorylation status [305, 331], the expression of iEGs 
(immediate Early Genes) [317, 334, 335] or the presence of phosphorylated/dephosphorylated 
isoforms of some proteins related to synaptic plasticity [259, 317, 336]. 
Considering the literature, we can define two different stages of synaptic potentiation during 
LTP: 
 
1) “short-term effects” (or Early-LTP, E-LTP) due to post-translational modifications of 
synaptic proteins, as well as alteration of their availability in correspondence of 
postsynaptic density [273]. Accordingly, it was demonstrated that αCaMKII-
phosphorylation in KCl-LTP models was necessary for the cell surface delivery of 
AMPARs in hippocampal cultures [266, 267, 270, 280].  
 
2) “long-term effects” (or Late-LTP, L-LTP) due to activity-dependent transcription, which is 
coupled to a PKA/MAPKs signaling pathways [322], and protein synthesis [262]. The 
events occurring during E-LTP, such as the recruitment of calcium-permeable AMPARs, 
can explain the activation of signaling pathways that in L-LTP drives spine morphological 
changes [234, 235, 270, 281]. New proteins reinforce the synaptic changes initiated during 
E-LTP, leading to the strengthening of the inter-neuronal transmission.  
 
The same stages are present also in LTD [316]. 
Some authors describe a very precocious stage, which lasts only 15 min and is called STP 
(Short Term Potentiation) [317]. 
In neurons, an activity-dependent protein synthesis has been found to be related to the late 
phase of LTP [148, 153, 159], a long-term memory formation [160, 161] and seizure [146, 
157, 158]. Protein synthesis starts within the first minutes of neuronal activation, depending 
on a coordinated program of stimulated gene transcription and translation, and the new 
proteins exert their functions during Late-LTP [272, 273, 352, 353]. In 1986, Goelet et al. 
proposed that iEGs, such as c-fos, might mediate the late phase of memory acquisition [138,  
143, 144, 146, 147, 175]. We now recognize that iEGs and specific transcription factors are 
the most important mediators between L-LTP and the functional/structural changes of 
synapses [188-192, 273, 159, 277]. The iEGs-induction has been well studied in many cell 
types [176-179] and appears to be regulated mainly by alteration in intracellular calcium ions 
[180-182, 189-191, 193-195], in response to a variety of external stimuli, including 
neurotransmitters, growth factors and membrane depolarization [139, 140, 141]. The modality 
of induction follows a similar pattern in different in vitro and in vivo models: mRNA 
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transcription occurs within 5 min and reaches the steady-state level in 30-45 min, while 
protein synthesis starts at least 30 to 45 min after the stimulus and the peak can be reached 
even 2 hours after the stimulation [137, 139, 140, 142, 232, 233]. NMDA-Rs are strictly 
involved in the activation signals of the early transcriptional events; indeed specific inhibitors 
prevent glutamate-mediated induction of iEGs-mRNA both in vitro and in vivo [141, 143-
145, 148-152]. 
Interestingly, new evidences suggest that LTP requires an initial period of activity-dependent 
translation of pre-existing mRNA which reinforces the switch from Early to Late LTP 
mechanisms [159]. Some authors described this reinforcement of E-LTP mechanisms as an 
“intermediate” phase [159, 282]. Pre-existing mRNA translation is essential for the late phase 
of LTP in the CA1 region also in spines and “isolated” dendritic preparations [115, 260-264, 
306, 307, 312-314]. NMDA-Rs directly promote the translation of pre-existing mRNAs [95, 
233] mainly in the soma but also in the dendritic processes. The activity-dependent translation 
has been described for some iEGs, such as Arc and αCaMKII, highly abundant in dendrites 
[115, 143, 154, 155, 233, 234, 236, 239, 252-254], permitting a rapid increase of their protein 
expression levels 3-10 min after NMDA-Rs activation. The new synthesis in loco of Arc and 
αCaMKII is important to regulate L-LTP, while the post-translational modification of 
αCaMKII (autophosphorylation after 1 min of neuronal activation [270, 276]) is important to 
permit and regulate E-LTP related processes [233, 234, 252-254, 270, 159, 276, 280, 283-
286, 292-294]. Indeed, the activated αCaMKII is translocated to the PSD and phosphorylates 
AMPA-Rs [317]. Both, the new protein synthesis in loco and the targeting to synapses of 
proteins synthetized in the soma are important to guarantee the “synapse-specificity” of 
plasticity.  
Molecularly, the translation of pre-existing mRNA during E-LTP is given by an increase in 
the phosphorylation of the eukaryotic initiation factor 4E (eIF4E), mediated by the opening of 
NMDA-Rs [95, 233, 237,307].  
Some recent papers confirmed the link between neuronal activation and changes in both the 
expression level and the sub-cellular distribution of CDKL5 [63, 64]. Therefore, we wanted to 
decipher both of these aspects during KCl-stimulation of neurons in vitro and ex vivo.    
In non-stimulated cultured neurons, Cdkl5 expression level increases during neuronal 
maturation and distributes between the nucleus and the cytosol [54, 63]. We found that, in 
cortical and hippocampal cultured neurons at different stages of maturation  (DIV3, DIV7 and 
DIV12), as well as in adult mouse cortical slices (P35-P38), a KCl-bath of 5 min induces the 
expression of Cdkl5 (+60%). This increase is due to a new synthesis of the kinase since it is 
abolished by blocking translational elongation through cycloheximide treatment. According to 
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literature, other proteins, such as Erk-1/2 and c-Fos, did not show any change in their 
expression level after 5 min of treatment. Similarly, Cdkl5 induction was observed 
stimulating for 5 min at DIV12 cultured hippocampal neurons (characterized by receptorial 
maturity [183]) with BDNF, which is known to regulate Early-LTP processes by activating 
the peripheral translation of mRNA and the trafficking of eIF4E into spines [159, 252-254, 
287-289]. 
This early induction of CDKL5 might suggest a requirement of novel synthesis of the kinase 
for early/intermediate phase of LTP. This hypothesis has to be confirmed through 
electrophysiological experiments performed on stimulated neurons ablated for Cdkl5.  
In hippocampal cultured neurons, calcium entry and the activity of NMDA-Rs and AMPA-
Rs, as well as the PKA and MAPKs activity, are required for observing the Cdkl5 response to 
KCl. 
Since we were interested in examining whether Cdkl5-transcription was increased  as well. 
Cdkl5-mRNA was quantified in KCl-depolarized neurons. An increased expression of Cdkl5-
mRNA and c-fos-mRNA was found after 5 min of KCl administration, suggesting a reactivity 
of Cdkl5 to neuronal activation similar to that of iEGs. The augmented level of Cdkl5-mRNA 
was probably due, similarly to c-fos, to increased transcription of the gene, since it was 
abolished by pre-treating neurons with the transcriptional repressor actinomycin-D. 
Interestingly, in analogy with the Arc-gene [233], we identified in the regulatory sequences of 
Cdkl5 a CRE motif (cAMP response element; TGAGCTCA) and in the future it would be 
interesting to investigate whether it has a role in the transcriptional activation.  Summarizing, 
we can conclude that after 5 min of exposition of cultured neurons to an elevated level of 
extracellular K+, or BDNF, there is an increase in Cdkl5 expression levels and the activation 
of its transcription. The precocious mRNA-translation is mediated by the opening of NMDA-
Rs and the subsequent activation of PKA and MAPKs, probably through the involvement of 
specific regulators, such as Mnk1 and eIF4E.    
Generally, factors induced during LTP increase their expression at the beginning of 
stimulation, reach a plateau and then return to control levels [188, 196, 197]. Therefore, we 
wanted to investigate whether CDKL5 was characterized by a similar behavior. DIV3/7 
hippocampal neurons were exposed to KCl for different time points and we observed such a 
triphasic profile by western assay, whereas no changes in the subcellular distribution of Cdkl5 
were detected by immunofluorescence. 
Interestingly, after returning to basal levels, Cdkl5 expression decreased rapidly and 
dramatically, suggesting an active degradation in depolarized neurons, both at DIV3 and 
DIV7. A significant decrease of Cdkl5 expression level was evident also in cortical slices 
54 
treated for 1 hour with KCl, while the same treatment did not cause the degradation of the 
LTP-related proteins Erk-1 and Erk-2. We demonstrated that a KCl-dependent degradation 
mediated by the proteasome is present only when the synapses are getting matured (DIV7) but 
not before this stage. Accordingly, at DIV7, but not at DIV3, Cdkl5 shows a proteasome 
dependent constitutive turnover.  
The ubiquitin-proteasome system is the major pathway for protein degradation in cells [266]. 
It is important to note that the expression of proteasome is very precocious in neurons, 
probably being already present at DIV3 in neurons [198, 199]. Furthermore, synaptic activity 
promotes proteasome sequestration within spines for the consolidation of the Early-LTP into 
Late-LTP, similarly to the activity-dependent mRNA-translation [233, 255, 257, 258, 262, 
263, 264, 266, 290]. 
Both L-LTP and the late phase of the NMDA-Rs-related LTD are dependent on both protein 
synthesis and proteasome activation [159]. Although LTP and LTD specific gene expression 
profiles have not been fully characterized so far [159], there are important suggestions 
regarding a balance between protein-synthesis and protein-degradation during synaptic 
activation, mainly involving some plasticity-related proteins in the synapses. This balance 
could explain the restore of L-LTP when both proteasome and protein synthesis inhibitors are 
co-applied [262, 291].  
Considering all above, we can hypothesize that CDKL5 levels could be yet another important 
element involved in the balance of synaptic protein composition during both Early- and Late- 
LTP. A further indication might be given by a recent publication demonstrating a co-
localization of CDKL5 with PSD95 and excitatory synapse markers [64].  
Eventually, we found that neuronal depolarization affects Cdkl5 post-translational 
modifications.  In particular, electrophoretic mobility studies suggested that Cdkl5 in non-
stimulated neurons and cortical slices is constitutively phosphorylated, similarly to ERK-7, a 
member of the MAPK family [109]. Indeed, KCl treatment leads to a rapid and progressive 
dephosphorylation of Cdkl5. So far, very little is known about the “phosphorylation status” of 
CDKL5. The kinase is capable of autophosphorylating its TEY motif [55, 61], but the 
involved stimuli are unknown.  
Increased phosphorylation of MAPKs and other plasticity-related proteins has been associated 
to LTP, whereas their dephosphorylation has been linked to LTD.  Particularly, LTP and LTD 
are related respectively to the inhibition or to the activation of protein phosphatases, such as 
PP1/PP2A (Phosphoprotein phosphatase 1; Phosphoprotein phosphatase 2A), as well as 
protein kinases [321],  regulating the reversible phosphorylation of synaptic proteins, such as  
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αCaMKII, AMPA-Rs and NMDA-Rs [200, 204, 208, 209-211, 213, 214, 255-264, 301, 321, 
322].  
After synaptic maturation, NMDA-Rs activation results in the recruitment of PP1 to the 
synapses [219] where presumably it can target synaptic proteins, raising the intriguing 
possibility that the pattern of synaptic activity controls the phosphorylation status of Cdkl5, a 
kinase localized at excitatory synapses [64]. Thus, we wanted to study the putative 
involvement of endogenous phosphatases in this activity dependent dephosphorylation of 
Cdkl5. The PP1/PP2A mediate a basal process of dephosphorylation of Cdkl5 and, when 
inhibited by okadaic acid (O.A.), the kinase is “hyperphosphorylated”. The PP1/PP2A are 
also involved, directly or indirectly, in the KCl-dependent dephosphorylation of Cdkl5, since 
the “large double band”, corresponding to a progressive dephosphorylation of Cdkl5, is not 
detectable if the inhibition of the phosphatases precedes KCl treatment, while tyrosine 
phosphatases appear to be unrelated with this process. Interestingly, KCl-dependent 
dephosphorylation of Cdkl5 occurs in neurons at DIV7 but not in less mature neurons at 
DIV3, therefore correlating with the development of more complex systems related to 
synaptic transmission. Considering that PP1, which regulates many processes in young 
neurons (the formation of filopodia, the maturation of neuronal filopodia into dendritic spines, 
the functional maturation of excitatory synapses, the axonal targeting [217, 218]), is 
precociously and ubiquitously expressed in mouse embryo brain (starting from E15.5) and in 
plated cortical neurons [215, 216], we speculate that PP1 is present at DIV3 hippocampal 
neurons but the maturation of other interacting proteins bridging PP1 to Cdkl5 (probably in 
the PSD fraction) is required to trigger the activity dependent dephosphorylation of Cdkl5 
observed at DIV7. Furthermore, we hypothesize that Cdkl5 dephosphorylation represents a 
signal for the activation of its proteasomal degradation, indeed Cdkl5 becomes a target of the 
proteasome, both in basal condition and during depolarization, only in DIV7 neurons.   
Chen et al. reported a transient increase in CDKL5 phosphorylation 5 min after BDNF 
stimulation of DIV5 rat cultured cortical neurons, suggesting the presence of rapid post-
translational modifications of the kinase during neuronal activation [56]. Thus, we 
investigated the presence of post-translational modifications, presumably activating the kinase 
and indicating a putative role during E-LTP, soon after KCl treatment of DIV7 hippocampal 
neurons. Interestingly, after a long gel running, we identified the presence of a different 
isoform of Cdkl5, which remains to be characterized but is certainly regulated, either directly 
or indirectly, by PP1/PP2A.  
In conclusion, considering some similarities, during neuronal activation, between the behavior 
of CDKL5 and other molecules known to have a role in LTP (NMDA-Rs related intra-cellular 
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pathways, transcriptional/translational activation, post-translational modifications, sensitivity 
to the proteasome), we propose CDKL5 as a new kinase involved in LTP (Fig. 21). New 
insights in the future are required to confirm the role of CDKL5 in LTP using both 
electrophysiological approaches and studies addressing whether the kinase interacts with 
other LTP-related molecules (ion channels, membrane receptors, transcription factors etc.). A 







Fig. 21 CDKL5 is sensitive to neuronal activity and shows similarities to some molecules involved in 
synaptic plasticity, suggesting a role of the kinase in the LTP. During the first minutes of stimulation, 
CDKL5 expression levels increase and the protein undergoes rapid post-translational modifications, compatible 
with a role during the E-LTP. After more than 5 minutes of stimulation, the behavior of CDKL5 in KCl treated 
neurons is different depending on the maturational stage of the cells: in immature neurons, the expression levels 
increase from 5 min to 1 hour; conversely, in mature neurons, a mechanism involving CDKL5 
dephosphorylation and degradation is active, suggesting that low levels CDKL5 are required during L-LTP at 











Primary cortical and hippocampal cultures were prepared from brains of CD1 mouse 
embryos at 18 days (E18). The mice were sacrificed by cervical dislocation; brains were 
removed from the embryos and the cortex and hippocampus rapidly dissected. After two 
washes in HBSS (GIBCO), neurons from the cortex and the hippocampus were dissociated by 
15’ incubation at 37°C in 0,25% trypsin (Sigma Aldrich). The cells were suspended with 
“dissection medium” [D-MeM with GlutaMAX-I (Gibco), horse serum 10%, 2 mM-L-
Glutamine (Sigma), 1 mM NaPyruvate (Gibco)] to block the action of the trypsin. Finally, 
counting the cells in a Bürker chamber, the definitive Neurobasal medium (Gibco) was added 
to the cells (supplemented with B27 (Gibco) and 2 mM-L-Glutamine) that were plated on 
Poly-L-lysine hydrobromide (Sigma P2636) coated dishes (0.1 mg/ml) or glass coverslips (1 
mg/ml). The number of the plated cells is reported in the following table: 
 
 
    number of cells 
cortical neurons, dishes 26.000 cells/cm2 
cortical neurons,  
glass coverslips 
2.500 cells/cm2 
hippocampal neurons, dishes 16.000 cells/cm2 




After 3 days in vitro (DIV), cytosine-1-b-D-arabinofuranoside (Ara-c, Sigma Aldrich), at the 
final concentration of 2 µM, was added to prevent astroglial proliferation.   
 
 
Treatments of cultured cells: 
Neurons were treated after 3, 7, and 12 days in vitro (DIV) with KCl at a final concentration 
of 50-55 mM. The Neurobasal medium contains 5 mM KCl, which corresponds to the 
physiological range. We used two different protocols of KCl-stimulation: 
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1) 5 min (minutes) KCl treatment: the cells were stimulated in Krebs-Ringer solution 
(KRH; KH2PO4 1.2 mM; MgSO4 1.2 mM; CaCl2 2 mM; Hepes pH 7.5 25 mM; 
glucose 1.1 mg/ml) with KCl 50 mM and NaCl 85 mM. The “control cells” were 
simultaneously treated with an isotonic bath in KRH with 5 mM KCl and 130 mM 
NaCl.  
2) Time course (5, 20, and 40 min; 1 hour, 3 hours) with 55 mM KCl.  
 
Treated and control cells were collected directly in Laemmli buffer. 
When necessary, KCl-dependent depolarization was anticipated by incubating with EGTA (2 
mM, 20 min), UO126 (10 µM, 20 min; Promega), H-89 (20 µM, 30 min; Cell Signaling), 
wortmannin (2 µM, 30 min; Sigma Aldrich), AP5 (100 µM, 30 min; Sigma Aldrich), CNQX 
(40 µM, 30 min; Sigma Aldrich),  
Actinomycin-D (20 µg/ml; 1 hour; Sigma Aldrich), cycloheximide (40 µM; 30 min; Sigma 
Aldrich).  
Neurons were also exposed to specific activators like Forskolin (100 µM, 5 min; Sigma 
Aldrich), NMDA (50 µM, 5 min; Sigma Aldrich) and BDNF (50 µg/ml, 5 min; Sigma 
Aldrich). Treated and control cells were collected directly in Laemmli buffer. 
 
 
KCl-treatment of mouse brain slices 
WT C57Bl6J female mice were anesthetized at P35-P38 with halothane (Sigma-Aldrich, 
Milan, Italy) and decapitated. The brain was quickly removed and put in ice-cold cutting 
solution (NaCl 125 mM; KCl 2.5 mM; NaH2PO4 1.25 mM; NaHCO3 26 mM; glucose 10 
mM; CaCl2 2 mM; MgCl2 1 mM) saturated with 95% oxygen and 5% CO2 (pH 7.4). 200 
μm-thick cortical-subcortical coronal frontal slices (anteriorly to the lateral ventricle) were 
then cut on the vibratome Leica VT1000S and maintained at 32°C for 30 min and at 25°C for 
other 30 min in the same buffer to allow functional recovery. 
Recovered slices were incubated in perfusion chamber and perfused (1 ml/min) at room 
temperature for 5 min, 20 min and 1 hour with gassed (95% 02/5% CO2) solution (KH2PO4 
1.25 mM, MgSO4 1.3 mM, CaCl2 2.5 mM, NaHCO3 17.6 mM, D-glucose 10 mM, pH 7.4) 
containing isomolar low or high [K+] (NaCl 125 mM, KCl 3 mM or NaCl 98 mM, KCl 30 
mM, respectively) in accordance with a previously published protocol [222].  After perfusion, 
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the slides were rapidly lysed in a potter with 200 ul of lysis buffer (PMSF 1 mM, Tris HCl pH 
7,4 50 mM, NaCl 150 mM,  Triton X-100 1%, EDTA 2mM, DTT 1mM, NaF 1mM, Na3VO4 
1mM, Phosphatse Inhibitor Cocktail (Roche), Protease Inhibitor Cocktail Sigma)) and the 
protein content of the samples was measured using the Bio-Rad Bradford method. Finally, the 




The lentiviral knock-down construct, sh-Cdkl5, were generated by cloning a short hairpin 
sequence against Cdkl5-mRNA (5’-CTATGGAGTTGTACTTAAAT-3’) into pLentiLox 3.7 
that also expresses GFP from an independent promoter. As control, a shLacZ construct, 
directed against β-galactosidase, was used. Recombinant lentivirus was produced by 
cotransfecting the pLentiLox 3.7 plasmid with the packaging vectors pREV, VSVG and 
pMDL into 293T cells. The viral particles were collected 36 hours post-transfection and 
concentrated by ultracentrifugation at 20.000 rpm for 2 hours. The viruses were resuspended 
in PBS and stored at -80°C. 
Cultured hippocampal neurons were infected at DIV0 (2 hours after plating) and collected at 
DIV7 after pharmacological/KCl treatment. Samples (300.000 cells silenced with 3 µl of 
vector concentrated stock [109 viral particles/ml] [223-225]) were collected directly in Laemli 
buffer 1X and processed by Western blot to confirm GFP expression and Cdkl5 silencing. For 
RT-qPCR analysis, cells were collected in RLT buffer (RNeasy Mini Kit Cat. No. 74104, 
QIAGEN) and analyzed as described in the section “Gene expression analysis”. 
 
 
Gene expression analysis: 
 
* RNA preparation and real-time qPCR 
Total RNA was isolated from treated neurons using the “miRNeasy mini Kit” 
(Cat.No.217004; QIAGEN) according to the manufacturer's instructions.   Contaminating 
DNA was removed with DNA-free reagent (RQ1 RNase-free DNase Cat.# M6101; Promega) 
and extracted RNA was quantified with Biotech Ultrospec 2000 UV visible 
spectrophotometer and its quality assessed through agarose gel electrophoresis (denaturing 
1% gel with EtBr).  
cDNA was synthetized from 200 ng of RNA using the “SuperScript II Reverse Transcriptase” 
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Kit (Cat. No. 18064-014; Invitrogen) as indicated by manufacturers. Quantitative Real-Time 
PCR was performed using 10 ng of cDNA mixed with the “GoTaq® qPCR Master Mix” 
(Ref.A6002, Promega) and the following primers:   
 
mCDKL5 forward:  TTCCCAGCTGTTAACCATCC 
mCDKL5 reverse:  AAGGAGACCGGTCCAAAAGT 
c-Fos forward:  GGCAAAGTAGAGCAGCTATCTCCT 
c-Fos reverse:  TCAGCTCCCTCCTCCGATTC 
mGAPDH forward:  AAGGTCGGTGTGAACGGATTTG 
mGAPDH reverse:  GCAGTGATGGCATGGACTGTG 
 
The RT-qPCR reaction was performed according to the following conditions:  
 
1) Mix:  
GoTaq® qPCR Master Mix: 1X 
Primer Mix 0,6 µM 
cDNA: 10 ng 
H2O (total volume 25 µl) 
 
2) Program: 
95°C 3 min 
Loop: 40 cycles (95°C 15 sec, 60°C 30 sec, 72°C 30 sec.) 
 
The reactions were performed with Multiplate PCR plates™Low 96-Well White 
(Cat.No.MLL9651, Bio-Rad) using a real-time cycler BioRad/MJ Research Chromo4. 
Each sample was assayed in triplicate, and the experiment was repeated three times. The data 
were analyzed using the DDCT method: replicates were averaged and compared to the mean 
value of the normalizer GAPDH in the same sample. A melting curve was automatically 
generated for each sample and confirmed that a single amplicon was generated in each 
reaction. 
 
* RT2 Profiler PCR arrays 
Total RNA from DIV7 hippocampal cultures was isolated as above using the RNeasy® Mini 
Kit (Cat. No. 74104, QIAGEN) and purified from contaminating DNA directly in the RNeasy 
Spin Column Membrane (DNase I Stock Solution QIAGEN). Cdkl5-silenced and control 
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hippocampal neurons treated with KCl at DIV7 were collected (300.000 cells per sample) 
directly in RLT buffer with 40 uM DTT (RNeasy Mini Kit QIAGEN) and processed as 
following. Extracted RNA was quantified with Varian Cary 50 scan UV-visible 
spectrophotometer and the quality assessed calculating the O.D. 260/280 ratio after 
spectrophotometer quantification and through a denaturing 1% agarose gel (with EtBr). 
350 ng of RNA was retro-transcribed using “RT2 First Strand Kit” (330401; QIAGEN) and 
gene transcription profiling was analyzed using the “RT2 Profiler™ PCR Arrays” technology 
(QIAGEN), following the procedures illustrated in the “RT2 Profiler™ PCR Array User 
Manual”. cDNA was added to “RT2 SYBR Green ROX™ qPCR Mastermix” (330522, 
QIAGEN) and the mix was aliquoted into “RT2 Profiler PCR Array Format C” (96 wells) 
(PAMM-126ZA, QIAGEN). Next, the real-time PCR cycling program was run into a Bio-
Rad/MJ Research Chromo4 real-time cycler, programmed according to the following table:   
 
















Data analysis was performed as indicated in the RT2 Profiler™ PCR Array User Manual. 
Results were obtained analyzing three DIV7 hippocampal cultures and 2 Cdkl5-silenced 
DIV7 hippocampal cultures treated or not with KCl. 
 
 
In vitro dephosphorylation assay 
For analyzing the phosphorylation status of endogenous murine Cdkl5, we collected 
hippocampal DIV7 neurons (300.000) before or after KCl treatment, directly in lysis buffer 
(Protease Inhibitor Cocktail Sigma, PMSF 1 mM, NP40 1%, Tris-HCl pH8 50 mM, EDTA 1 
mM, NaCl 150 mM, DTT 0,5 mM, SDS 0,1%) with or without phosphatase inhibitors (NaF 1 
mM; NaVO4 1 mM; Phosphatase Inhibitor Cocktail (Roche)). Protein concentration was 
estimated using the Bradford method (Bio-Rad). An amount of 50 µg of total protein from the 
lysate was exposed to 800U of lambda phosphatase (Lambda-PPase, BioLabs) in PPase 
Reaction Buffer (Tris-HCl 50mM; DTT 5mM; EDTA 0,1mM; Brij 35 0,01%; pH 7.5), 
supplemented with 2 mM MnCl2, for 3 hours at 30°C. The reactions was stopped by 
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incubation at 65°C for 15 min and the samples analyzed by immunoblotting. 
 
 
PP1/PP2a inhibition assay 
Cultured hippocampal neurons (DIV7) were treated with 1 µM okadaic acid (O.A.; Sigma 
Aldrich) for 45 min or with 1 mM sodium orthovanadate ( Na3VO4, Sigma Aldrich) for 1 hour 
and then depolarized with the addition of 50 mM KCl for 5 and 20 min.  
 
 
Proteasome inhibition assay 
Hippocampal neurons (DIV7 and DIV3) were treated with MG132 (50 μM; Sigma Aldrich), a 
proteasome inhibitor, for 6 hours. Treated and control cells were collected directly in 
Laemmli buffer.  When necessary, 3 hours-KCl treatment was anticipated by MG132 (50μM; 
Sigma Aldrich) pre-treatment for 3 hours.  
 
 
Western Blotting Analysis 
Western blot analysis was performed using standard methods. 30 µl of the lysate was heated 
(at 70°C when we wanted to preserve phosphorylation, otherwise at 98°C), separated by 8% 
SDS-PAGE (Acrylamide solution Euro-Clone, Mix 37,5:1) and transferred to nitrocellulose 
membranes. To enhance the separation of phosphorylated and non-phosphorylated Cdkl5 
isoforms, a 7% SDS-PAGE was prepared with a particular concentration of the two forms of 
acrylamide (acrylamide/bisacrylamide Mix 77:1). Filters were developed by using a 
chemiluminescence-based detection system (SuperSignal West Pico Chemiluminescent 
Substrate Pierce; GE Healthcare, Piscataway, NJ) and quantified by scanning densitometry 
using the QuantityOne software package (Bio-Rad, Hercules, CA, USA). To evaluate 
phosphorylation, we made a ratio between the normalized phospho-protein and the 




Hippocampal E18 neurons were seeded on glass coverslips. At DIV7 the cells were treated 
with KCl and fixed by 4% paraformaldehyde (PFA) in HBSS (15 min), washed and subjected 
to immunofluorescence. After 1 hour in permeabilization-blocking buffer (0,2% triton X-100, 
5% foetal bovine serum in PBS) at room temperature the neurons were incubated overnight at 
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4°C with primary antibodies in 5% foetal bovine serum and 0,1% triton X-100. After 24 
hours, cells were rinsed in PBS three times and incubated with the secondary antibodies (anti-
rabbit Alexa Fluor 555 and anti-mouse Alexa Fluor 488, Invitrogen) in blocking solution for 1 
hour at room temperature. Nuclei were stained with DAPI (Sigma) and the signal was 




The following antibodies were used for western blotting and immunofluorescence 
experiments 
- Rabbit polyclonal anti-CDKL5 antibody (Sigma Prestige HPA002847; 0,37mg/ml) 
- Purified Mouse monoclonal α-tubulin Sigma T6074 (specific for human, mouse, rat) 
- Affinity isolated rabbit polyclonal antibody anti-MeCP2 Sigma M9317 (a.a. 465-478); 0,6 
mg/ml 
- Polyclonal rabbit antibody anti-Erk-1|2 (C-terminal 35 a.a. in human and mouse) Millipore 
Cat.#06-182  
- Rabbit polyclonal anti-phospho-p44/42 Erk (Thr202/Tyr204) antibody, Cell Signaling 
#9101 
- Mouse monoclonal anti-GAD67 Millipore Cat.#MAB5406 
- Anti-GFP mouse monoclonal antibodies Roche Cat.No.1814460 
- Monoclonal mouse anti-neuronal class III-beta-tubulin (clone TUJ1) antibodies, Covance 
MMS-435P; 1mg/ml 
- Rabbit polyclonal cleaved caspase-3 (Asp175) antibody, Cell Signaling #9661 
- Rabbit polyclonal anti-GAPDH antibody Millipore AB2302 
- HRP-conjugated goat anti-mouse or anti-rabbit secondary antibodies for Western 
blotting from Thermo Scientific 
- Secondary Alexa Fluor anti-rabbit and anti-mouse antibodies (and DAPI) for 




All values are expressed as the average of at least three different experiments ± standard error 
(S.E.M.). The significance of results was evaluated by Student's t test, and statistical 
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